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The citrus flavonoid nobiletin has lipid lowering and insulin sensitizing properties. In mice, 
nobiletin supplementation prevents high fat diet-induced dyslipidemia and insulin resistance. 
Interestingly, triglyceride mass remains elevated in the intestine of fasted high fat-fed mice, 
but not in nobiletin-supplemented mice. In this thesis, the mechanisms underlying the 
prevention of intestinal triglyceride retention by nobiletin were investigated. In male Ldlr-/- 
mice, nobiletin corrected intestinal insulin signaling resulting in normalization of de novo 
lipogenesis and decreased triglyceride for chylomicron synthesis and storage. In response to 
an oral fat load, nobiletin increased chylomicron-triglyceride secretion into plasma and 
enhanced plasma triglyceride clearance resulting in attenuated postprandial lipemia. 
Nobiletin also normalized gut hormone signaling and pancreatic β-cell mass to prevent 
hyperinsulinemia. Although nobiletin increased plasma GLP-2, GLP-2 antagonist 
administration did not inhibit nobiletin-induced chylomicron secretion. Finally, nobiletin 
protected high fat-fed female Ldlr-/- mice from dysregulated intestinal triglyceride 
metabolism but not from atherogenic cholesterol metabolism. These studies provide evidence 
for the therapeutic utility of nobiletin in improving intestinal insulin signalling and intestinal 









Insulin resistance, lipid and lipoprotein metabolism, obesity, citrus flavonoids, dyslipidemia, 
cardiovascular disease. 
Summary for Lay Audience 
A natural compound isolated from tangerine peels called nobiletin has beneficial properties 
including improving the action of insulin. Insulin is a hormone secreted from the pancreas 
into the blood stream after a meal that helps cells of our body to use and store the energy 
(glucose) from our diet. Overconsumption of high-calorie foods causes an over-secretion of 
insulin and eventually, cells become resistant to insulin action. When we feed mice a high-fat 
diet, they develop insulin resistance, obesity, high levels of blood fats (such as cholesterol) 
and fat accumulates in fat cells as well as in other organs such as the liver. Previously, we 
have reported that in mice, adding nobiletin to a high-fat diet corrects insulin resistance, 
prevents obesity, lowers blood fats and prevents liver fat accumulation. Nobiletin works by 
increasing the burning of fats in the liver. The small intestine, which is responsible for 
absorbing and packaging dietary fat for delivery into the bloodstream, has been shown to 
contribute to dangerous blood fat levels. We asked the question – Does nobiletin also 
improve the way the small intestine handles fat? Intriguingly, when mice are fed a high-fat 
diet, but not a low-fat diet, the small intestine accumulates fat, even in the fasted state. The 
addition of nobiletin to the high-fat diet completely prevented this fasting fat accumulation. 
In this thesis, we studied how nobiletin prevents fasting intestinal fat accumulation. In male 
mice, nobiletin prevented insulin resistance in cells of the intestine resulting in the 
normalization of the amount of fat stored. In response to a fat meal, nobiletin increased the 
rate at which packaged fat exits the intestine and enters the blood stream. Once in the blood, 
the rate at which this blood fat was cleared from the circulation was much faster compared to 
mice fed the high fat diet alone. In the pancreas, nobiletin normalized insulin stimulation and 
decreased insulin storage to prevent high-blood insulin. We also investigated the protective 
effects of nobiletin, for the first time, in female mice. Nobiletin prevented obesity and fasting 
fat accumulation in the intestine. While some blood fats were normalized with nobiletin 
treatment, cholesterol levels were just as high as in the mice fed the high-fat diet alone. These 




they highlight the potential of nobiletin as a treatment and they demonstrate the importance 
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Chapter 1  
1 Introduction 
Cardiovascular diseases (CVDs) are the leading causes of death in the world [1]. A major 
contributor to CVDs in Western countries is atherosclerosis [1]. This progressive disease 
is characterized by an accumulation of lipid-rich necrotic debris, smooth muscle cells, 
and cholesterol-overflowing macrophages in large arteries [2]. These accumulations lead 
to plaque formation, which grow into lesions in the blood vessel wall [2]. These lesions 
can either grow large enough to block blood flow or rupture to form a devastating 
thrombus, resulting in a heart attack or a stroke [2]. The development of effective 
therapeutics depends on our understanding of the underlying mechanisms leading to 
atherosclerosis. 
1.1 Lipoproteins 
The insolubility of lipids, such as cholesterol and triglycerides, requires their transport to 
be associated with proteins in blood [3]. Lipoproteins are composed of a hydrophobic 
core, which contains non-polar lipids such as cholesteryl ester and triglycerides [3]. This 
core is surrounded by phospholipids, free cholesterol and apolipoproteins that together 
form a hydrophilic monolayer [3]. The different sizes, lipid compositions and 
apolipoprotein signatures of the lipoprotein distinguish plasma lipoproteins into seven 
classifications (Table 1) [3]. Moreover, the apolipoprotein signatures are largely 
responsible for the metabolic fate of these lipoproteins.  
Chylomicrons produced by the intestine and are mainly composed of triglycerides on an 
apolipoproteinB48 (apoB48) protein scaffold. They are the largest plasma lipoprotein and 
are responsible for the transport of dietary fat to peripheral (non-liver) tissues [4, 5]. 
VLDL particles are liver-derived and are mainly composed of triglycerides on an 
apoB100 protein scaffold [3]. While VLDL particles are smaller than chylomicron 
particles, their size reflects the amount of endogenous triglyceride synthesized in the liver 
[3]. Catabolism of VLDL particles results in cholesterol-enriched intermediate density 
lipoprotein (IDL) [3]. Derived from VLDL and IDL particles are the low-density 
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lipoproteins (LDL), the primary blood cholesterol carrier in humans [3]. Finally, HDL 
particles are synthesized primarily in the  circulation on a apoA-1 protein scaffold and are 
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Adapted from Doonan et al. (2019) Biochem Biophys Acta. 1863: 762-771  
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1.2 Lipoprotein metabolism 
1.2.1 Exogenous lipoprotein metabolism 
Enterocytes, the absorptive cells in the gut, are dynamic responders to the ingestion of 
food [6] and are responsible for absorbing and packaging lipids for distribution as 
chylomicrons throughout the body. Greater than 95% of dietary fat is absorbed, while 
approximately only 50% of dietary cholesterol is absorbed following the consumption of 
a meal [3]. Once in the lumen of the small intestine, pancreatic lipase hydrolyzes dietary 
triglycerides into free fatty acids and monoacylglycerols [7]. Hydrolyzed fats associate 
with bile acids, cholesterol, phospholipid, plant sterols, and fat-soluble vitamins to form 
mixed micelles, which facilitate both passive and active transport of FAs into the 
enterocyte [3]. While the entire small intestine is biologically capable of absorbing 
dietary fat, the jejunum performs the bulk of this process [5]. CD36 is a fatty acid 
transporter highly expressed in jejunal villi responsible for some FA absorption, whereas 
the remainder crosses the brush border membrane by passive diffusion [3]. Cholesterol 
and plant sterol absorption, on the other hand, is facilitated by Niemann-Pick C1-like 1 
protein (NPC1L1), whose activity is inhibited by ezetimibe as a cholesterol-lowering 
therapy [3].  
 Upon entry into the enterocyte, cholesterol and plant sterols are subject to one of 
two fates: transport back into the intestinal lumen by the ABCG5 and ABCG8 
heterodimer sterol transporter, or conversion to sterol esters by acyl-CoA cholesterol acyl 
transferase (ACAT) [3]. Approximately 95% of plant sterols and 50% of dietary 
cholesterol are transported back into the lumen by ABCG5 and ABCG8 [3]. In parallel, 
fatty acid binding proteins transport absorbed fatty acids to the endoplasmic reticulum 
(ER) of the enterocyte [5]. Here, fatty acids are resynthesized into triglyceride while 
cholesterol is converted to cholesteryl ester by ACAT. Acyl-CoA synthetase activates 
fatty acids to fatty acyl-CoA [5, 7]. Fatty acyl-CoAs are primarily incorporated into 
triglyceride molecules in the fed-state, where monoacylglycerol acyltransferase (MGAT) 
catalyzes the addition of one FA-CoA to a monoacylglycerol [5]. Triglyceride formation 
is completed by the actions of diacylglycerol transferase (DGAT), which catalyzes the 
addition of FA to diacylglycerol. At this point, triglycerides and cholesterol esters are 
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catalyzes the addition of one FA-CoA to a monoacylglycerol [5]. Triglyceride formation 
is completed by the actions of diacylglycerol transferase (DGAT), which catalyzes the 
addition of FA to diacylglycerol. At this point, triglycerides and cholesterol esters are 
subjected to one of two fates: they are either loaded onto the newly synthesized apoB48 
scaffold protein for chylomicron secretion into circulation or they enter cytoplasmic lipid 
droplets (CLDs) for temporary storage within the enterocyte [4, 7, 8]. 
1.2.1.1 Apolipoprotein B-48 (apoB48) 
Each chylomicron particle contains one apoB48 protein, which serves as a scaffold 
protein essential for chylomicron synthesis and secretion [3-5]. Dietary fat stimulates the 
production of apoB48 in intestinal enterocytes from the apoB primary sequence. During 
translation, a large multiprotein complex including (apobec)-1 converts codon 2153 
(CAA) to a premature stop codon (UAA) in apoB mRNA; this truncation event yields 
48% of the mature apoB sequence [9]. As a result, the C-terminal portion of apob48 lacks 
the LDL receptor-binding domain, thus preventing hepatic uptake and clearance of 
chylomicrons [9]. Importantly, APOBEC-1 arises from the APOBEC1 gene, which is 
highly expressed in the small intestine and is absent in the liver in humans [9]. Mice, 
however, express Apobec-1 in both the liver and the intestine, allowing both apoB100 
and apoB48 to be produced in the liver [5]. 
1.2.1.2 Chylomicron assembly and secretion 
Microsomal triglyceride transfer protein (MTP) assists in apoB folding and catalyzes the 
transfer of triglycerides, cholesteryl esters and phospholipids onto apoB48 as it is being 
translated into the ER lumen [9]. The resulting primordial chylomicron particle 
undergoes further lipidation and acquires ApoA-IV, forming a pre-chylomicron particle 
[9]. Pre-chylomicron transport vesicles facilitate the export of pre-chylomicrons from the 
ER to the Golgi [9]. This complex fuses with the cis-Golgi, where transported pre-
chylomicron particles acquire Apo-AI and Apo-AII, forming mature chylomicron 
particles. Vesicles then transport mature chylomicrons from the Golgi to the enterocyte's 










Figure 1-1 Triglyceride processing in intestinal enterocytes. 
Pancreatic lipases in the intestinal lumen hydrolyze dietary triglyceride (TG) into 
monoacylglycerol (MG) and fatty acids (FA). CD36, fatty acid binding protein (FABP) 
and fatty acid transporter protein facilitate FA absorption into the enterocyte. In the 
enterocyte, FAs are re-esterified into TG in the endoplasmic reticulum (ER) first by mono 
acylglycerol transferase (MGAT) and then by diacylglycerol acyltransferase (DGAT) 1 
or 2. TG within the ER can either be stored in cytoplasmic lipid droplets (CLD) for 
temporary storage, or it can be transferred to the Golgi where it is loaded onto apoB48 
scaffold protein for chylomicron formation.  












































1.2.1.3 Chylomicron catabolism 
Chylomicrons are secreted into the lymph, where they acquire apoC-II, C-III and E 
mainly from HDL [9]. Chylomicrons enter the circulation at the left subclavian vein via 
the thoracic duct [5], which is specifically designed for primary delivery of energy-rich 
fatty acids to the energy-demanding heart. Lipoprotein lipase (LPL) is highly expressed 
in heart, muscle and adipose tissue and is anchored to glycosylphosphatidylinositol 
anchored high density lipoprotein binding protein 1 (GPI-HBP1) on the luminal surface 
capillary endothelial cells [3, 9]. LPL hydrolyzes TG within the core of postprandial 
chylomicrons and its activity is modulated by chylomicron-associated apoC-II 
(activation) and apoC-III (inactivation) [9]. Most of the released fatty acids cross 
endothelial cells and are transported by CD36 and FAPBs into peripheral tissues for 
energy production or storage, while some bind to albumin for transport to other tissues 
[3]. The resulting triglyceride-depleted and now cholesterol-enriched chylomicron 
remnant acquires apo E from HDL in exchange for phospholipids, apoAs and apoCs. Apo 
E facilitates chylomicron remnant binding to the LDL or LRP receptor on the hepatocyte 
membrane for uptake into the liver [3]. Once peripheral tissues acquire triglycerides from 
chylomicron particles, the resulting particle is now smaller, enriched in cholesteryl ester 
and is called the chylomicron remnant [3].  
 Overall, chylomicron particles enable efficient delivery of dietary fatty acids to 
the periphery for energy utilization and storage. Chylomicron remnant particles enable 
the delivery of dietary cholesterol to the liver for VLDL and bile acid synthesis [3]. 
Under normal conditions, there is little difference between the number of apoB48-
containing particles secreted from the intestine in the fasting and postprandial states; their 
size, rather, depends on the amount and type of fat absorbed [9]. 
Gender, genetics, age, body size, exercise, weight loss and metabolic syndrome (MetS) 
influence postprandial lipid secretion [9]. Furthermore, fatty acid composition 
significantly alters postprandial lipid secretion, where meals enriched in n-3 
polyunsaturated fatty acids decrease postprandial triglyceride secretion compared to 
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meals high in saturated and monounsaturated fatty acids [9]. There is epidemiological 
evidence that both fasting and postprandial hypertriglyceridemia are important risk 
factors for CVD. 
1.2.1.4 Cytoplasmic lipid droplets (CLD) 
As previously mentioned, triglycerides derived from dietary fatty acids that are not 
assembled into the primordial chylomicron particle are temporarily stored into CLDs. 
Budding of excess triglyceride molecules from the smooth endoplasmic reticulum is 
currently the most supported proposed mechanism for CLD synthesis [5]. CLDs continue 
to accumulate triglycerides and increase in size through triglyceride synthesis at the CLD 
surface, phospholipid synthesis for monolayer expansion and by fusing with other CLDs 
[5]. While generally much larger than chylomicrons, CLDs share some similar features 
such a large triglyceride and cholesteryl ester cores surrounded by a monolayer of 
phospholipids, free cholesterol and proteins, including perilipins [5]. 
 Dietary fat consumption increases the number and size of CLDs in mice, where 
the majority of CLDs are found in enterocytes of the proximal jejunum [5]. CLD 
synthesis appears to attenuate FA toxicity and control chylomicron synthesis and 
secretion rates in response to high-fat challenges [5]. The number and size of CLDs 
decrease with fasting time, suggesting that CLD stored triglycerides are hydrolyzed at 
later time points and released fatty acids are either re-synthesized into triglycerides for 
chylomicron synthesis and secretion, directed toward fatty acid oxidation or are used for 
other cellular purposes [5, 8]. Emerging studies underline the importance of intestinal 
FA-oxidation activity in altering enterocyte triglyceride storage. In mice, chronic high-fat 
feeding upregulates FA-oxidation and corresponding gene expression compared to low-
fat fed mice. This upregulation in FA-oxidation may be important in providing additional 
energy to enterocytes required for the increased dietary fat absorption or in limiting FA 
availability to reduce postprandial lipemia [5]. Cytoplasmic lipolysis and/or lysosomal 
lypolysis (lipophagy) have been proposed as mechanisms of CLD catabolism, although 
the complete mechanism has not been fully elucidated. Important players in CLD 
lipolysis that have been identified on these structures in enterocytes using proteomics 
include adipocyte triglyceride lipase (ATGL). In particular, triglyceride storage in CLDs 
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inversely correlates with enterocyte ATGL activity, which hydrolyzes triglyceride ester 
bonds and directs the products towards oxidation [5]. Emerging studies have identified 
CLDs as substrates for autophagy, where autophagosomes engulf CLDs and deliver them 
to the lysosome; here, lysosomal acid lipase (LAL) hydrolyzes ester bonds. While a 
relatively new area of research, diet, hormones, transcription factors and signaling 
systems have all been identified as regulators of enterocyte CLD metabolism [5]. 
1.2.2 Endogenous lipoprotein metabolism 
Hepatocytes are the workhorses of the hepatic lipid metabolism whereby they are 
responsible for lipid uptake, esterification, oxidation, storage and secretion of VLDL 
[10]. Sources of hepatic FAs include diet (15-30%), de novo lipogenesis (up to 30%) and 
FAs released from adipose tissues during fasting [10]. VLDL synthesis begins with 
apolipoprotein B-100 (apoB100) translocation across the endoplasmic reticulum (ER) 
membrane [11]. MTP, like in the intestine, facilitates the partial lipidation of apoB with 
triglyceride, cholesteryl ester and phospholipid during the translation of apoB 
polypeptide, which also prevents its degradation [10, 11]. The resulting pre-VLDL 
particle fuses with neutral lipid droplets in the ER lumen to continue lipidation [11]. 
Therefore the availability of triglycerides drives the rate of VLDL synthesis. Next, VLDL 
particles are transported to the cis-Golgi by VLDL transport vesicles for glycosylation 
and phosphorylation. VLDL-containing secretory vesicles fuse with the sinusoidal 
membrane and are then secreted into the space of Disse, and into circulation where the 
acquire apoCII, CIII and some apoE from HDL [11]. VLDL particles are transported in 
the circulation and triglycerides are hydrolyzed by capillary endothelial cell-bound LPL 
and therefore compete with chylomicrons for clearance [9]. VLDL hydrolysis results in 
the formation of smaller, denser, cholesteryl ester-enriched intermediate density 
lipoproteins (IDL) that acquire more apoE from HDL particles [12]. At the hepatocyte 
cell surface, IDL particles are further depleted of triglyceride by hepatic lipase or LPL. 
Approximately 50% of these modified IDL particles are cleared by the liver via binding 
of apoE to LDL and LRP receptors, while the remaining ~50% becomes LDL, the 
predominant cholesteryl ester carrier in the circulation [12]. Therefore VLDL metabolism 
produces LDL particles. 
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 Since LDL particle production depends on IDL particle availability for 
triglyceride depletion, LDL particle production is also under the regulation of LDLR 
activity [3]. In other words, a decrease in LDLR activity will lead to an increase in LDL 
particle production. Moreover, approximately 70% of LDL particles are cleared by liver 
LDLR mediated endocytosis [3]. An increase in hepatic LDLR number will lead to an 
increase in LDL particle clearance and therefore a decrease in plasma LDL.   
1.2.2.1 The LDL receptor (LDLR) 
The LDLR has a well-established role in clearing circulating lipoprotein particles [13]. 
The LDLR localizes to the cell surface and contains five functional domains: the ligand 
binding domain, the epidermal growth factor (EGF) receptor homology domain, the O-
linked glycosylation domain, the hydrophobic transmembrane domain and the 
cytoplasmic domain [14]. The N-terminus is the ligand-binding domain, by virtue of its 
negatively charged region, which interacts with the positive charges present on apoB and 
apoE proteins thereby enabling the clearance of LDL, chylomicron remnants and IDL 
particles [3,14]. The EGF domain contains a region for n-linked glycosylation, which is 
required for secretion of LDLR, and the binding domain for proprotein convertase 
subtilisin/kexin type 9 (PCSK9) [12]. The O-linked glycosylation domain is also 
extracellular and is required for secretion [14]. The hydrophobic nature of the fourth 
domain allows for receptor anchorage to the cell surface. The final domain of the LDLR 
is the C-terminus cytoplasmic tail, which is required for anchorage and contains the 
NPxY sequence; this sequence directs the LDLR to clathrin-coated pits for endocytosis in 
response to the binding of LDLR associated protein 1 (LDLRAP1) [14]. Once 
internalized into endosomes, the LDLR can dissociate from the lipoprotein and be 
recycled to the cell surface; the endosome fuses with lysosomes resulting in lipoprotein 
degradation and release of cholesterol to the ER membrane. Alternately, internalization 
of LDLRs bound to PCSK9 are not recycled and are targeted for lysosomal degradation 
[12].  
 Hepatocytes continuously sense the cholesterol availability within the cell, 
primarily within the ER, and respond to maintain homeostasis. The expression of LDLR 
at the cell surface is inversely related to the intracellular cholesterol content [13]. At the 
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gene expression level, low cellular cholesterol triggers the translocation of transcription 
factor SREBP from the endoplasmic reticulum to the Golgi. Activation of SREBP at the 
Golgi allows for migration to the nucleus and subsequent initiation of the expression of 
the LDLR as well as HMG-CoA reductase, the rate-limiting enzyme in cholesterol 
synthesis [3]. High cellular cholesterol levels not only keep SREBP inactive in the 
endoplasmic reticulum, but they also oxidize as they accumulate [3]. Oxidized sterols 
also keep SREBP inactive, but they can activate LXR, a nuclear hormone receptor that 
stimulates transcription of E3 ubiquitin ligase called inducible degrader of the low-
density lipoprotein receptor (IDOL). As the name suggests, IDOL targets LDLR for 
degradation [3]. Therefore, the cell can regulate its cholesterol content by controlling 
endogenous synthesis and well as LDLR mediated lipoprotein cholesterol uptake from 
the circulation. 
1.2.3 Reverse cholesterol transport 
To maintain cellular cholesterol homeostasis, HDL transports excess peripheral 
cholesterol to the liver for excretion into bile and feces [15]. The intestine and the liver 
synthesize and secrete apoA-I, the main structural protein for HDL formation [9]. 
Following secretion, apoA-I acquires cholesterol by interacting with the cholesterol 
transporter ATP Binding Cassette AI (ABCA1) expressed by hepatocytes and enterocytes 
[16]. The resulting pre-β HDL particles continue to acquire free cholesterol and 
phospholipids from peripheral cells via ABCA1 as well as from the lipolysis of 
chylomicrons and VLDL particles. The latter process partly contributes to the strong 
inverse correlation between triglycerides and HDL-cholesterol [3, 16]. HDL-apoA-I 
activates lecithin cholesteryl acyl transferase (LCAT), which catalyzes the 
transesterification of fatty acids from phospholipids to the free cholesterol to form 
cholesteryl ester. This newly formed cholesteryl ester is more hydrophobic and localizes 
from the surface monolayer to the core of the growing HDL particle [3, 16, 17]. These 
more mature HDL particles can acquire more cholesterol from peripheral cells via 
ABCG1. In humans, CETP facilitates the transfer of cholesteryl ester from HDL to apoB 
containing particles in exchange for triglyceride for further metabolism. Mice, however, 
do not express CETP and therefore have relatively high HDL cholesterol levels and low 
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LDL cholesterol levels [3]. The liver selectively takes up HDL cholesteryl ester via 
scavenger receptor BI (SR-B1) and the resulting smaller apoA-I containing HDL particle 
returns into the circulation [16]. The delivered cholesterol can either be converted to bile 
acids or directly secreted in bile. The latter process is achieved by liver ABCG5 and 
ABCG8, which are under the regulation of LXR [3]. 
1.3 Fatty acid and cholesterol metabolism 
1.3.1 Fatty acid and triglyceride synthesis 
De novo lipogenesis is the insulin-dependent synthesis of fatty acids from carbohydrates 
[32]. Insulin-sensitive liver and adipose tissues perform de novo lipogenesis to provide 
energy to peripheral tissues via lipoproteins and to store excess energy long-term, 
respectively [10, 32, 33]. Intramitochondrial citrate derived from glycolysis is transported 
to the cytoplasm where ER-bound ATP citrate lyase cleaves citrate to acetyl-CoA and 
oxaloacetate [11]. In the cytosol, a series of coordinated decarboxylative condensation 
reactions occur in which acetyl-CoA is converted into malonyl-CoA by acetyl-CoA 
carboxylase (ACC) [11]. Malonyl-CoA is subject to subsequent elongation reactions 
catalyzed by the multi-subunit fatty acid synthase (FAS), ultimately generating 16- and 
18-carbon saturated fatty acids [11]. In the cytosol, acyl-CoA synthetase activates fatty 
acids to acyl-coenzyme esters to enable their entry into lipid synthesis or fatty acid 
oxidation [34].    
 The fatty acyl-CoA chains used for triglyceride synthesis originate from de novo 
lipogenesis or from adipose tissue lipolysis [32]. Triglyceride synthesis occurs through 
the glycerol phosphate pathway in most tissues or the monoacylglycerol pathway, where 
the latter is quantitatively more important within enterocytes. The enzyme glycerol-
phosphate acyl transferase (GPAT) catalyzes the addition of fatty acyl-CoA to glycerol-
3-phosphate, producing lysophosphatidic acid [11]. Next, lysophosphatidic acid is 
acylated by one of several acyl-CoA:lysophosphatidic acid acyltransferases to produce 
phosphatidic acid, which is then dephosphoylated to generate diacylglycerol (DAG). The 
final acyl-CoA is added to DAG by diacylglycerol acyl transferase (DGAT), forming a 
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triglyceride molecule [11]. The resulting triglycerides are either stored as CLDs or are 
used for VLDL assembly (liver) or chylomicron assembly (intestine) [11]. 
1.3.2 Cholesterol synthesis and esterification 
Cholesterol is an essential 27-carbon steroid present in the membranes of all mammalian 
cells and is involved in bile salt and steroid hormone synthesis [35]. The first step in 
cholesterol synthesis involves the enzymatic combination of acetyl-CoA with 
acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). HMG-
CoA is reduced to mevalonate by HMG-CoA reductase, the rate-limiting step in 
cholesterol biogenesis and the target for statin drugs. Through a series of phosphorylation 
and condensation reactions, mevalonate is converted to a 30-carbon squalene molecule 
[35]. The cyclization of squalene yields lanosterol, which after several modifications is 
converted to one cholesterol molecule [35]. Cells must maintain cholesterol homeostasis 
membrane proteins functioning, however, too much cholesterol causes membrane 
toxicity. Therefore, free cellular cholesterol is converted to cholesterol ester by addition 
of acyl-CoA (primarily olelyl-CoA) catalyzed by ACAT for storage in CLDs or addition 
to the core of chylomicrons or VLDL particles [36].  
1.3.3 Regulation of triglyceride and cholesterol synthesis 
Dietary and endogenous pathways provide lipids for energy, cellular membrane 
components and precursor molecules [37]. To maintain energy homeostasis, the synthesis 
of lipids is tightly regulated by allosteric and transcriptional control. 
1.3.3.1 Regulation of de novo lipogenesis 
Sterol regulatory element binding proteins (SREBPs) coordinate fatty acid and 
cholesterol synthesis [38]. The SREBP family consists of SREBP-1a, SREBP-1c (both 
produced from SREBP-1) and SREBP-2 (produced from SREBP-2) isoforms [38]. The 
N-terminal domain in SREBP proteins is a basic-helix-loop-helix-leucine zipper (BHLH-
Zip) structure responsible for DNA binding and activation of transcription [38]. These 
proteins also contain 2 hydrophobic membrane-spanning sequences and a regulatory C-
terminal domain [38]. Normally, the precursor forms of SREBP remain bound to the 
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endoplasmic reticulum membrane through the actions of SREBP cleavage-activating 
protein (SCAP) and insulin-induced gene (INSIG), forming an INSIG-SCAP-SREBP1 
complex [11]. When stimulated by insulin signaling or by low cellular sterol levels, 
conformational changes in SCAP cause INSIG to dissociate from the SCAP-SREBP 
complex, thereby enabling transport of the SCAP-SREBP precursor complex from the 
ER to the Golgi [11]. Golgi site 1 and 2 proteases (SIP/S2P) cleave the precursor protein 
[11]. The N-terminal active domain is then released and can enter the nucleus to promote 
the expression of target genes [37]. SREBP-2 promotes the expression of cholesterogenic 
genes, whereas SREBP-1c promotes the expression of lipogenic genes [37]. Insulin, via 
mTORC1 (outlined in 1.6.1), induces SREBP-1c activation at the transcriptional level 
[37]. Therefore, nutritional status regulates the expression of SREBP-1c. SREBP1c 
phosphorylation is promoted by an inhibition of its phosphatase, lipin 1. When activated 
by oxysterols, liver X receptor (LXR)α, induces SREBP-1c transcription. Target genes of 
SREBP-1c include lipogenic genes FAS, ACC and SCD-1 [37]. 
1.3.4 Fatty acid oxidation 
During fasting, adipose tissue lipolysis of TGs and de novo synthesis pathways can 
provide fatty acids for oxidation as a source of energy [34]. Fatty acids undergo oxidation 
primarily through β-oxidation in the mitochondrial matrix. Short- and medium- chain 
fatty acids pass directly through the mitrochondrial membrane [32]. Longer acyl-CoA 
molecules, however, cannot penetrate the mitochondrial membrane [34] and require 
carnitine palmitoyltransferase 1 (CPT-I) to convert them to acyl-carnitine molecules for 
transport across the mitochondrial membrane [32, 34]. Once within the matrix, CPT-II 
converts long chain fatty acids to their acyl-CoA form [32]. β-oxidation consists of 4 
enzymatic steps, where each cycle releases acetyl-CoA that can be used for the 
tricarboxylic acid cycle [34]. Furthermore, electrons are transferred from the fatty acyl-
CoA to reduce flavin-adenine dinucleotide (to FADH2) and to the oxidized form of 
nicotinamide-adenine dinucleotide (to NADH) [32, 34]. These coenzymes donate 
electrons to the electron transport chain to drive ATP synthesis [32]. 
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1.3.4.1 Regulation of fatty acid oxidation 
To prevent simultaneous oxidation and synthesis of fatty acids within a cell, malonyl-
CoA, the product of the first step of de novo fatty acid synthesis, is an allosteric inhibitor 
of CPT-I activity [32]. Fatty acid oxidation is also controlled at the transcriptional level 
by a class of ligand-activated receptors, peroxisome proliferator-activated receptors 
(PPARs) [34]. The presence of fatty acids activates PPARs, which then dimerize with 
retinoid X receptor (RXR), a nuclear receptor [34, 39]. This heterodimer then binds to 
PPAR response elements (PPREs) in the promoter of target genes [34]. The PPAR family 
includes PPARα, PPARβ⁄δ and PPARγ. PPARα controls fatty acid oxidation gene 
expression in the liver whereas PPARβ⁄δ control those in the skeletal muscle and heart 
[34]. PPARγ is highly expressed in the intestine [40]. 
1.4 Insulin signaling 
Insulin is the central hormone involved in nutrient-metabolism communication. Under 
normal conditions, dietary glucose stimulates insulin secretion from pancreatic β-cells 
into the circulation to promote glucose uptake into muscle and adipose tissue, protein and 
glycogen synthesis in muscle and liver as well as lipogenesis and lipid storage in the liver 
and adipose tissue [11, 18-20]. Concomitantly, insulin signaling inhibits lipolysis of TGs 
stored in adipose tissue, suppresses hepatic gluconeogenesis and glucose secretion, and 
inhibits fatty acid oxidation [21]. 
The insulin receptor is a plasma membrane glycoprotein consisting of an extracellular α-
subunit and a transmembrane β-subunit with tyrosine kinase activity. The binding of 
insulin to the α-subunit first triggers receptor dimerization, forming an α2 β2 complex, 
and second, autophosphorylation of the β-subunit [19]. The active insulin receptor 
recruits and phosphorylates several substrates that lead to the activation of two important 
signaling cascades; namely, the mitogen-activated protein kinase (MAPK) pathway and 
the phosphoinositide 3-kinase (PI-3K) pathway [19]. The MAPK cascade mediates 
insulin-stimulated mitogenesis and cellular growth, whereas the PI-3K cascade mediates 
insulin-stimulated metabolism [19]. 
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Insulin-stimulated activation of PI-3K produces phosphatidylinositol (3,4,5)-triphosphate 
(PIP3), a secondary messenger, which activates 3-phosphoinositide-dependent protein 
kinase-1 and -2 (PDK1 and PDK2) [19]. PDK1 and PDK2 phosphorylate Akt at tyrosine-
308 and serine-473, respectively, leading to complete Akt activation [19]. Akt activates 
downstream targets including forkhead box protein O1 (FoxO1) and mammalian target of 
rapamycin complex 1 (mTORC1) [18]. FoxO1 is a transcription factor that activates 
gluconeogenesis. Insulin-stimulated phosphorylation of FoxO1 prevents its translocation 
from the ER to the nucleus, thereby downregulating genes required for gluconeogenesis, 
such as glucose 6 phosphate [11, 20]. Activation of mTORC1 by phosphorylated Akt 
indirectly promotes the expression and nuclear localization of SREBP-1c, the 
transcription factor that activates de novo lipogenesis [19, 20]. Together, Akt acts as the 













Figure 1-2 Insulin signaling in an insulin sensitive liver. 
 In normal cells, insulin binds to and activates the insulin receptor (IR), resulting in 
receptor autophosphorylation and subsequent tyrosine phosphorylation of IR substrates 
(IR1/2). This initiates further downstream signals including activation of the serine kinase 
Akt via PI3K. Phosphorylation of mTORC1 by Akt induces activation of SREBP-1c, the 
master regulator of genes involved in fatty acid and triglyceride synthesis (de novo 
lipogenesis, DNL). Insulin activated Akt also stimulates the phosphorylation of FoxO1, 
resulting in its exclusion from the nucleus and subsequent prevention of the upregulation 
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1.4.1 Insulin resistance 
Resistance to the physiological actions of insulin results in impaired anabolic glucose 
metabolism and pro-atherogenic dyslipidemia [22, 23]. Insulin resistance is a central 
feature of MetS and type 2 diabetes, where insulin-resistant subjects display 
hyperinsulinemia, hyperglycemia and hypertriglyceridemia. In an effort to achieve 
insulin action in peripheral tissues, pancreatic β-cells expand and proliferate, resulting in 
hyperinsulinemia, a primary instigator to type 2 diabetes and cardiovascular dysfunction 
[19]. 
1.4.1.1 Hepatic insulin resistance 
Sources of uncontrolled blood glucose are 2-fold: reduction of blood glucose uptake from 
the circulation and impaired suppression of hepatic gluconeogenesis [23]. Impaired 
suppression of gluconeogenesis is due to an upregulation of transcription factor, FoxO1 
(lack of phosphorylation) in the liver. While the FoxO1 pathway becomes insulin 
resistant, insulin sensitivity is maintained in the mTORC1 pathway and is over-stimulated 
in the context of hyperinsulinemia [20]. As a result, SREBP-1c expression and activation 
are extremely high and fatty acid synthesis is accelerated [20]. Thus, excess triglycerides 
from hepatic de novo and ectopic sources cause an increase in hepatic VLDL assembly 
and secretion. This dichotomy was coined "selective insulin resistance" by Goldstein and 
Brown in 2008 and is likely explained by the divergence of insulin signaling downstream 










Figure 1-3 Insulin signaling in an insulin resistant liver.  
During the hyperinsulinemic state associated with insulin resistance, the mTORC1 
pathway remains sensitive to insulin, thereby amplifying SREBP-1c-mediated de novo 
lipogenesis. By contrast, Akt fails to phosphorylate FoxO1. As such, FoxO1 remains in 
the nucleus and upregulates the transcription of MTP (promotes VLDL formation), 















De novo Lipogenesis 
FoxO1 P 









1.4.1.2 Insulin resistance in peripheral tissues to the liver 
Obesity-induced over-expansion of adipose tissue induces hypoxia, triggering an 
inflammatory response and subsequent insulin resistance. As such, impaired insulin 
signaling at the level of the insulin receptor reduces glucose uptake in adipose tissue and 
downregulates cell surface expression of the major insulin-responsive glucose 
transporter, GLUT4 [23, 24]. In skeletal muscle, insulin signaling at the level of the 
receptor is also impaired and reduced glucose uptake is due to a reduction of GLUT4 
translocation, docking or fusion to the surface of muscle cells [24].  
Liver-derived hyperglycemia coupled with chronic hyperinsulinemia is thought to further 
impair insulin's ability to inhibit adipose tissue lipolysis [23]. As such, insulin-resistant 
adipocytes release higher levels of free fatty acids (FFAs), which accumulate in other 
tissues such as the liver thereby providing glycerol as a substrate for gluconeogenesis and 
FA substrate for triglyceride synthesis, VLDL production and hepatic lipid storage [21, 
23]. Furthermore, lipotoxicity resulting accumulation of ectopic fat derived from 
adipocyte lipolysis potentiates insulin resistance to other tissues [21, 23]. Finally, the 
increased production of cytokines by expanded adipose tissue reduces LPL expression, 
which contributes to hypertriglyceridemia observed in MetS [25]. 
1.4.1.3 Evidence for intestinal insulin resistance 
In chow-fed hamsters and normal humans, insulin acutely inhibits intestinal apoB48 
secretion [26, 27]. By contrast, acute elevations in plasma FFAs in hamsters and humans 
stimulates intestinal lipoprotein production [22]. Therefore, insulin-mediated suppression 
of plasma FFA, and the lack thereof in the setting of insulin resistance, effectively 
highlights the emerging concept that non-dietary sources of FA are important substrates 
for intestinal TG storage or TG-containing lipoprotein secretion. The influence of 
peripheral insulin resistance on intestinal-TG secretion is further displayed in insulin-
resistant subjects and fructose-fed hamsters, where an overproduction of triglyceride-rich, 
apoB48-containing chylomicrons is observed, resulting in increased and prolonged 
postprandial lipemia [22, 28]. Moreover, fasting plasma insulin positively correlates to 
postprandial TG, large VLDL particles and chylomicron remnants [29].  
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 Evidence for an intestinal specific resistance to insulin has also been documented. 
First, intestinal de novo lipogenesis does occur, and its activity positively correlates with 
intestinal expression of Srebf-1c [22]. Increased de novo lipogenesis was reported in 
primary enterocytes from fructose-fed hamsters [29]. In the same experiment, inhibition 
of fatty acid synthase decreased fasting apoB48 lipoprotein secretion [29]. Abnormal 
insulin signaling in insulin-resistant hamster enterocytes has also been observed; namely, 
decreased insulin receptor substrate activation, reduced Akt protein, increased PTP-1B 
protein and activated ERK1/2 [26]. The intestine has also been shown in rats to 
contribute to endogenous glucose production via gluconeogenesis, which is rapidly 
inhibited by insulin infusion [30]. Furthermore, the expression of gluconeogenic genes in 
the rat small intestine, such as glucose 6 phosphate, is strongly induced in fasting and 
diabetic states [31]. The bifurcation in insulin sensitivity or selective insulin resistance 
that has been well documented in the liver remains to be explored in the insulin-resistant 
intestine. 
1.5 Nutrient signaling in the gut 
Glucagon like peptide-1 (GLP-1 and glucose dependent insulinotropic polypetide (GIP) 
are incretin hormones secreted from the intestinal L-cells and K-cells, respectively, in 
response to glucose ingestion [41]. They activate their respective G protein coupled 
receptors, namely, the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR) to 
stimulate insulin secretion from pancreatic β-cells to ensure efficient glucose disposal 
[41]. In healthy humans, GLP-1 and GIP are responsible for 50-70% of glucose-
stimulated insulin secretion [42]. Dipeptidyl peptidase 4 (DPP4) is a circulating serine 
protease, also secreted from intestinal cells that truncates GLP-1 and GIP, rendering them 
biologically inactive [41]. DPP4 is therefore an important regulator of energy 
homeostasis. 
In the setting of type 2 diabetes (T2DM), the incretin effect of glucose-stimulated insulin 
secretion is significantly reduced; as such, DPP4 inhibitors are widely used to potentiate 
GLP-1 and GIP action [41]. Similarly, GLP-1R agonists are approved therapies for type 2 
diabetes. In T2DM cardiovascular safety trials, GLP-1R agonists were found to elicit 
significant decreases in major adverse cardiovascular events, partly due to GLP-1-
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mediated benefits on both fasting and postprandial lipid profiles [43]. In addition to 
nutrient-dependent insulin secretion, GLP-1 regulates postprandial lipid and lipoprotein 
metabolism. The posttranslational processing of the proglucagon gene in intestinal L cells 
in response to nutrient ingestion not only yields GLP-1, but also glucagon-like peptide 2 
(GLP-2) [43]. Moreover, GLP-1 and GLP2 are co-secreted from intestinal L-cells in a 1:1 
molar ratio when stimulated [4, 43]. These two hormones have opposing effects on 
metabolism, where GLP-1 lowers glycemia and post-prandial plasma chylomicron 
triglycerides and GLP-2 increases intestinal fat absorption and chylomicron-triglyceride 
secretion into plasma [44, 45]. While GLP-2 does not possess insulinotropic activity, 
GLP-2 promotes intestinal growth and enhances gut barrier function [42, 46]. As such, 
GLP-2R agonists have been successfully used to treat patients with short bowel syndrome 
[4, 42].  
The opposing roles of GLP-1 and GLP-2 on intestinal lipoproteins are not fully 
understood [4]. Despite being secreted in a 1:1 molar ratio, the degradation of GLP-1 and 
GLP-2 by DPP4 occurs at different rates, where the former has a half-life of 1.5 min and 
latter has a half-life of 7 min [43]. This level of complexity further challenges our 
understanding on how GLP-1 and GLP-2 regulate postprandial lipid metabolism. 
Furthermore, many of the described effects of these hormones were observed at 
pharmacological doses. As nutrients are potent stimulators of gut hormone secretion, 
nutraceuticals may prove to be attractive therapeutics for potentiating GLP-1 and GLP-2 
action [47]. 
1.6 Flavonoids 
Phytochemicals are abundant in nature; of these, flavonoids are of increased interest due 
to their significant biological benefits [48]. Flavonoids accumulate in the stems, flowers, 
leaves and fruits of plants and are involved in pigmentation, UV filtration, nitrogen 
fixation and antimicrobial properties [48]. Flavonoids are the most abundant polyphenol 
in the human diet; they are found in soy, fruits, vegetables, nuts, seeds, cocoa, coffee, 
wine and tea [49]. It is estimated that the average North American or European ingests is 
between 20 and 70 mg of flavonoids per day [48]. Their 15-carbon atom structures 
include three phenolic rings bound to one or more hydroxyl groups [49]. Their structure 
26 
 
and degree of oxidation divides them into 6 classes; namely, flavonols, flavones, 
isoflavones, flavanones, flavan-3-ols and anthocyanidins [50]. If glycosylated, hydrolysis 
occurs at the brush-border of the small intestine and the released lipophilic aglycone 
enters enterocytes by passive diffusion [51]. Here, aglycones are metabolized and their 
products enter portal circulation for phase II metabolism in the liver, however substantial 
quantities of absorbed aglycones pass from the small to the large intestine [51]. Here, 
colonic microbiota hydrolyze aglycones and these products can also be absorbed into the 
portal circulation. Flavonoid metabolites that are excreted in urine or in bile, however, 
often exceed those that enter circulation [51]. Therefore their abundance and 
bioavailability may limit their therapeutic potential, thus making purified forms of 
flavonoids attractive agents for investigation. 
1.6.1 Citrus flavonoids and cardiovascular risk 
Flavonoid structure enables their roles as reducing agents, hydrogen-donating 
antioxidants and oxygen quenchers: attractive features in a MetS setting [49]. 
Epidemiologically, a higher intake of flavonoids correlates with a lower cardiovascular 
risk [49]. In particular, citrus fruits represent a significant source of many types of 
flavonoids and intake has  been associated with a reduction in cardiovascular events [49]. 
Citrus flavonoids represent approximately 10 mg of the previously mentioned average 
daily flavonoid intake [49]. Polymethoxylated flavones including tangeretin, nobiletin 
and sinensetin are most abundant in the pith and peels of citrus fruits [49]. Drinking one 
glass of orange juice per day reduces the risk of stroke in men by 25%. In 69,622 female 
nurses, a 19% reduction in ischemic stroke risk was found in subjects with high 
flavanone intake through orange and grapefruit juices and fruits [49]. Together, multiple 
beneficial effects of citrus flavonoid consumption have been shown, however, their 
mechanisms of action are not completely established. 
1.6.2 Nobiletin 
This thesis focuses on a tangerine-derived, polymethoxylated flavonoid, nobiletin. 
Several earlier studies from our group and others have investigated the role of nobiletin in 
modulating lipid metabolism, glucose homeostasis and lipid metabolism. In HepG2 cells, 
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nobiletin robustly attenuated apoB100 secretion in a similar manner to insulin. Nobiletin 
increased LDLR expression and activity and decreased MTP and DGAT1/2 mRNA 
through the mitogen-activated protein kinase-extracellular (MAPK/ERK) signal-related 
kinase signaling pathway [52]. Unlike insulin, however, nobiletin did not induce 
phosphorylation of the insulin receptor or insulin receptor substrate-1. Importantly, 
nobiletin did not stimulate lipogenesis [52]. An unbiased chemical screen identified 
nobiletin as a clock-amplitude-enhancing small molecule [53]. In HepG2 cells, nobiletin 
modulated the AMPK-Sirt1 signaling pathway to prevent palmitate-induced lipogenesis 
in a Bmal1-dependent manner. Moreover, nobiletin attenuated secretions of reactive 
oxygen species induced by palmitate treatment [54]. 
Several studies have investigated the metabolic protection of nobiletin in vivo. A 
combination of tangeretin and nobiletin treatment improved glucose tolerance in 
hyperinsulinemic and hypercholesterolemic hamsters [55]. Nobiletin treatment to diet-
induced obese mice as well as in db/db mutant mice improved metabolic indices and 
increased energy expenditure in a Clock gene-dependent manner [53]. Retinoic acid 
receptor-related orphan receptors (ROR) were identified as direct targets of nobiletin 
[53]. In Ldlr-/- mice with diet-induced obesity, intervention by supplementation of 
nobiletin to a HFHC diet reversed existing obesity through enhanced energy expenditure 
and increased hepatic fatty acid oxidation [9]. Furthermore, nobiletin improved insulin 
sensitivity and hyperlipidemia in these mice [56]. In Ldlr-/- mice, supplementation of 
nobiletin to a high-fat Western-style diet prevented obesity, increased glucose tolerance 
and dramatically attenuated atherosclerosis. Nobiletin also prevented hepatic triglyceride 
accumulation by enhancing hepatic-fatty acid oxidation, interestingly, without activating 
any peroxisome proliferator-activated receptors (PPARs). Furthermore, nobiletin 
attenuated dyslipidemia by reducing VLDL-triglyceride secretion from liver into plasma 
[52]. This reduction in reduced VLDL-triglyceride secretion was attributed to nobiletin's 
ability to limit lipid accumulation in both the liver and the intestine. Of significance for 
this thesis, significant levels of triglyceride mass remained in the intestine of Western-fed 
mice following a 6 hour fast but not in mice fed the same Western diet supplemented 
with nobiletin [52]. The reasons for this effect are unknown. Therefore, the present 
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studies investigated the mechanism(s) through which nobiletin prevents high-fat diet-
induced fasting intestinal triglyceride accumulation. 
1.7 In vivo models used 
1.7.1 Mouse models 
Mice transport the majority of their plasma cholesterol on HDL particles, rendering them 
relatively resistant to cardiovascular disease [57]. Therefore, genetic and dietary 
manipulations of their lipid metabolism are required to study metabolic syndrome. The 
C57BL/6J mouse substrain is often used in metabolic studies, as they are susceptible to 
diet-induced diabetes and obesity [17].  Mice deficient of the receptor that clears 
atherogenic LDL and VLDL particles, Ldlr-/-  mice on a C57BL/6J background, develop 
moderate hypercholesterolemia and display a shift to elevated LDL cholesterol, similar to 
a human lipoprotein profile [57, 58]. These parameters are further increased when placed 
on a diet with containing greater than 20% kcals from fat, whereby they develop severe 
hyperlipidemia, become obese, display insulin resistance and develop extensive 
atherosclerosis, [58]. These features make Ldlr-/- mice a useful model for studying 
obesity and insulin resistance in the presence of dyslipidemia. 
1.7.2 Mouse diets 
1.7.2.1 Chow diet 
Laboratory chow (TD8604) was used as a control diet for metabolic indices altered by a 
high-fat, high-cholesterol diet. The chow diet contains complex carbohydrates and has a 
caloric density of 3.0 kcal/g (14% of calories come from fat). The chow diet was fed ad 
libitum to mice in all studies. 
1.7.2.2 High-fat, high-cholesterol diet 
The high-fat, high-cholesterol diet (HFHC) (TD09268) was used to induce obesity, 
hyperlipidemia and insulin resistance. Other studies in our lab used this diet to induce 
atherosclerosis [9,52]. The HFHC diet is composed of anhydrous milk fat and lard (58% 
saturated, 36% monounsaturated and 5% polyunsaturated fatty acids) and has a caloric 
density of 4.5 kcal/g (42% of calories come from fat). The carbohydrate sources are 
29 
 
sucrose (30% of calories) and corn starch (13% of calories), whereas the protein source is 
casein (15.2% of calories). The HFHC diet was fed ad libitum to the mice in all studies. 
Table 2.1 Mouse diets 










DL-Methionine ingredients, exact 3 amounts not specified 
Sucrose 341.46 
Corn Starch 150.75 
Anhydrous Milk Fat 160 
Lard (Pork) 50 
Cellulose 35.13 
Mineral Mix 50 
Zinc Carbonate 0.04 
Vitamin Mix 10 







Protein 24.3 (32) 17.3 (15.2) 
Carbohydrate 40.2 (54) 48.7 (42.8) 
Fat 4.7 (14) 21.2 (42) 
kcal/g 3.0 4.5 
Cholesterol (%wt) 0.005% 0.2% 
*Represented ingredients: Dehulled soybean meal, wheat middlings, flaked corn, 
ground corn, fish meal, cane molasses, ground wheat, dried whey, soybean oil, 
brewers dried yeast, dicalcium phosphate, calcium carbonate, iodized salt, choline 
chloride, kaolin, magnesium oxide, ferrous sulfate, vitamin E acetate, menadione 
sodium bisulfite complex (source of vitamin K activity), manganous oxide, copper 
sulfate, zinc oxide, niacin, thiamin mononitrate, vitamin A acetate, vitamin D3 
supplement, calcium pantothenate, pyridoxine hydrochloride, riboflavin, vitamin B12 






1.8 Hypothesis and scope of thesis 
Insulin resistance, a central component of MetS, is associated with increased VLDL 
production, HDL-cholesterol is decreased and LDL-cholesterol is increased, therefore 
posing a significant atherogenic risk. The dichotemy was coined "selective insulin 
resistance" in the liver by Goldstein and Brown in 2008, and helps to explain 
hyperglycaemia, hyperinsulinaemia and hypertriglyceridemia present in type 2 diabetes 
patients [20]. Although selective insulin resistance has been well documented in liver, it 
is possible that this also occurs in the intestine in insulin resistant states. Emerging 
evidence demonstrates that insulin-resistant subjects also overproduce triglyceride-rich, 
apoB48-containing chylomicrons, resulting in increased postprandial lipemia. While 
statin therapy aims to control LDL-cholesterol concentrations, postprandial 
hypertriglyceridemia continues to drive atherogenicity [59, 60], suggesting a further 
understanding of how dysregulated of intestinal lipoprotein metabolism contributes to 
plaque development is required.  
Supplementation of nobiletin to a high-fat, high-cholesterol (HFHC) diet in Ldlr-/- mice, a 
physiological model of MetS, prevents obesity, insulin resistance, hepatic steatosis, 
dyslipidemia and atherosclerosis, in part, through enhanced hepatic-fatty acid oxidation 
[52]. These previous studies were performed with a primary focus on the liver. The small 
intestine, however, is the first site of regulation of dietary fat and cholesterol; 
consequently, abnormal intestinal lipid metabolism could also promote MetS 
development, especially through its role in postprandial lipemia. Therefore, the small 
intestine represents a potential site of protection by nobiletin. Due to the evidence that 
hormonal and nutritional signals play a role in the initiation of intestinal lipoprotein 
formation [4], the purpose of these studies was to examine the metabolic effects of 
feeding both male and female mice a HFHC diet on the development of intestinal insulin 
resistance, intestinal lipid accumulation, postprandial chylomicron secretion and gut 
peptide secretion. Furthermore, the potential therapeutic effects of nobiletin to prevent 
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HFHC diet-induced dysregulation of intestinal lipoprotein metabolism were explored. 
Moreover, the ability of nobiletin to exert its preventative effects through GLP-2 
signalling, was investigated. 
This thesis will address the following hypothesis: 
Nobiletin prevents fasting jejunal lipid accumulation by correcting intestinal insulin 
signalling and enhancing intestinal triglyceride secretion into plasma. 
The specific aims of this thesis are as follows: 
Aim 1: Determine if nobiletin corrects intestinal insulin resistance. 
Aim 2: Determine if nobiletin improves oral glucose tolerance via intestinal incretin 
secretion. 
Aim 3: Determine if nobiletin alters the rate at which chylomicrons are secreted into 
plasma. 
Aim 4: Determine if reductions is intestinal triglyceride content by nobiletin are mediated 
by GLP-2. 










1. Lu, H. and A. Daugherty, Atherosclerosis. Arterioscler Thromb Vasc Biol, 2015. 
35(3): p. 485-91. 
2. Lusis, A.J., Atherosclerosis. Nature, 2000. 407(6801): p. 233-41. 
3. Feingold, K.R. and C. Grunfeld, Introduction to Lipids and Lipoproteins, in 
Endotext, K.R. Feingold, et al., Editors. 2000: South Dartmouth (MA). 
4. Mulvihill, E.E., Regulation of intestinal lipid and lipoprotein metabolism by the 
proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. Curr 
Opin Lipidol, 2018. 29(2): p. 95-103. 
5. D'Aquila, T., et al., Recent discoveries on absorption of dietary fat: Presence, 
synthesis, and metabolism of cytoplasmic lipid droplets within enterocytes. Biochim 
Biophys Acta, 2016. 1861(8 Pt A): p. 730-47. 
6. Hammond, K.A., et al., Simultaneous manipulation of intestinal capacities and 
nutrient loads in mice. Am J Physiol, 1996. 271(6 Pt 1): p. G969-79. 
7. Iqbal, J. and M.M. Hussain, Intestinal lipid absorption. Am J Physiol Endocrinol 
Metab, 2009. 296(6): p. E1183-94. 
8. Hung, Y.H., A.L. Carreiro, and K.K. Buhman, Dgat1 and Dgat2 regulate 
enterocyte triacylglycerol distribution and alter proteins associated with cytoplasmic lipid 
droplets in response to dietary fat. Biochim Biophys Acta Mol Cell Biol Lipids, 2017. 
1862(6): p. 600-614. 
9. Julve, J., et al., Chylomicrons: Advances in biology, pathology, laboratory testing, 
and therapeutics. Clin Chim Acta, 2016. 455: p. 134-48. 
10. Gluchowski, N.L., et al., Lipid droplets and liver disease: from basic biology to 
clinical implications. Nat Rev Gastroenterol Hepatol, 2017. 14(6): p. 343-355. 
33 
 
11. Sanders, F.W. and J.L. Griffin, De novo lipogenesis in the liver in health and 
disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc, 2016. 
91(2): p. 452-68. 
12. Ramasamy, I., Recent advances in physiological lipoprotein metabolism. Clin 
Chem Lab Med, 2014. 52(12): p. 1695-727. 
13. van de Sluis, B., M. Wijers, and J. Herz, News on the molecular regulation and 
function of hepatic low-density lipoprotein receptor and LDLR-related protein 1. Curr 
Opin Lipidol, 2017. 28(3): p. 241-247. 
14. Soutar, A.K. and B.L. Knight, Structure and regulation of the LDL-receptor and 
its gene. Br Med Bull, 1990. 46(4): p. 891-916. 
15. Yu, X.H., et al., Cholesterol transport system: An integrated cholesterol transport 
model involved in atherosclerosis. Prog Lipid Res, 2019. 73: p. 65-91. 
16. Rader, D.J. and G.K. Hovingh, HDL and cardiovascular disease. Lancet, 2014. 
384(9943): p. 618-625. 
17. Fontaine, D.A. and D.B. Davis, Attention to Background Strain Is Essential for 
Metabolic Research: C57BL/6 and the International Knockout Mouse Consortium. 
Diabetes, 2016. 65(1): p. 25-33. 
18. Titchenell, P.M., M.A. Lazar, and M.J. Birnbaum, Unraveling the Regulation of 
Hepatic Metabolism by Insulin. Trends Endocrinol Metab, 2017. 28(7): p. 497-505. 
19. Guo, S., Insulin signaling, resistance, and the metabolic syndrome: insights from 
mouse models into disease mechanisms. J Endocrinol, 2014. 220(2): p. T1-T23. 
20. Brown, M.S. and J.L. Goldstein, Selective versus total insulin resistance: a 
pathogenic paradox. Cell Metab, 2008. 7(2): p. 95-6. 
21. Sears, B. and M. Perry, The role of fatty acids in insulin resistance. Lipids Health 
Dis, 2015. 14: p. 121. 
34 
 
22. Adeli, K. and G.F. Lewis, Intestinal lipoprotein overproduction in insulin-resistant 
states. Curr Opin Lipidol, 2008. 19(3): p. 221-8. 
23. Czech, M.P., Insulin action and resistance in obesity and type 2 diabetes. Nat 
Med, 2017. 23(7): p. 804-814. 
24. Kahn, B.B. and J.S. Flier, Obesity and insulin resistance. J Clin Invest, 2000. 
106(4): p. 473-81. 
25. Mead, J.R., S.A. Irvine, and D.P. Ramji, Lipoprotein lipase: structure, function, 
regulation, and role in disease. J Mol Med (Berl), 2002. 80(12): p. 753-69. 
26. Federico, L.M., et al., Intestinal insulin resistance and aberrant production of 
apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic 
dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular 
signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed 
hamster intestine. Diabetes, 2006. 55(5): p. 1316-26. 
27. Pavlic, M., et al., Insulin acutely inhibits intestinal lipoprotein secretion in 
humans in part by suppressing plasma free fatty acids. Diabetes, 2010. 59(3): p. 580-7. 
28. Lewis, G.F., et al., Postprandial lipoprotein metabolism in normal and obese 
subjects: comparison after the vitamin A fat-loading test. J Clin Endocrinol Metab, 1990. 
71(4): p. 1041-50. 
29. Haidari, M., et al., Fasting and postprandial overproduction of intestinally derived 
lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose 
feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and 
ApoB48-containing lipoprotein overproduction. J Biol Chem, 2002. 277(35): p. 31646-
55. 
30. Croset, M., et al., Rat small intestine is an insulin-sensitive gluconeogenic organ. 
Diabetes, 2001. 50(4): p. 740-6. 
35 
 
31. Rajas, F., et al., The glucose-6 phosphatase gene is expressed in human and rat 
small intestine: regulation of expression in fasted and diabetic rats. Gastroenterology, 
1999. 117(1): p. 132-9. 
32. Nguyen, P., et al., Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl), 
2008. 92(3): p. 272-83. 
33. Ameer, F., et al., De novo lipogenesis in health and disease. Metabolism, 2014. 
63(7): p. 895-902. 
34. Houten, S.M., et al., The Biochemistry and Physiology of Mitochondrial Fatty 
Acid beta-Oxidation and Its Genetic Disorders. Annu Rev Physiol, 2016. 78: p. 23-44. 
35. Alphonse, P.A. and P.J. Jones, Revisiting Human Cholesterol Synthesis and 
Absorption: The Reciprocity Paradigm and its Key Regulators. Lipids, 2016. 51(5): p. 
519-36. 
36. Chang, T.Y., et al., Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol 
Endocrinol Metab, 2009. 297(1): p. E1-9. 
37. Eberle, D., et al., SREBP transcription factors: master regulators of lipid 
homeostasis. Biochimie, 2004. 86(11): p. 839-48. 
38. Brown, M.S. and J.L. Goldstein, The SREBP pathway: regulation of cholesterol 
metabolism by proteolysis of a membrane-bound transcription factor. Cell, 1997. 89(3): 
p. 331-40. 
39. Watanabe, M. and H. Kakuta, Retinoid X Receptor Antagonists. Int J Mol Sci, 
2018. 19(8). 
40. Marion-Letellier, R., G. Savoye, and S. Ghosh, Fatty acids, eicosanoids and 
PPAR gamma. Eur J Pharmacol, 2016. 785: p. 44-49. 
36 
 
41. Mulvihill, E.E., Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control 
of the incretin axis and regulation of postprandial glucose and lipid metabolism. Peptides, 
2018. 100: p. 158-164. 
42. Baggio, L.L. and D.J. Drucker, Biology of incretins: GLP-1 and GIP. 
Gastroenterology, 2007. 132(6): p. 2131-57. 
43. Xiao, C., et al., Gut Peptides Are Novel Regulators of Intestinal Lipoprotein 
Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism. 
Diabetes, 2015. 64(7): p. 2310-8. 
44. Hsieh, J., et al., Glucagon-Like Peptide 2 (GLP-2) Stimulates Postprandial 
Chylomicron Production and Postabsorptive Release of Intestinal Triglyceride Storage 
Pools via Induction of Nitric Oxide Signaling in Male Hamsters and Mice. 
Endocrinology, 2015. 156(10): p. 3538-47. 
45. Qin, X., et al., GLP-1 reduces intestinal lymph flow, triglyceride absorption, and 
apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol, 2005. 288(5): 
p. G943-9. 
46. Drucker, D.J. and B. Yusta, Physiology and pharmacology of the enteroendocrine 
hormone glucagon-like peptide-2. Annu Rev Physiol, 2014. 76: p. 561-83. 
47. Cani, P.D., et al., Improvement of glucose tolerance and hepatic insulin sensitivity 
by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes, 2006. 
55(5): p. 1484-90. 
48. Xiao, J., Dietary flavonoid aglycones and their glycosides: Which show better 
biological significance? Crit Rev Food Sci Nutr, 2017. 57(9): p. 1874-1905. 
49. Mulvihill, E.E., A.C. Burke, and M.W. Huff, Citrus Flavonoids as Regulators of 
Lipoprotein Metabolism and Atherosclerosis. Annu Rev Nutr, 2016. 36: p. 275-99. 
50. Mulvihill, E.E. and M.W. Huff, Antiatherogenic properties of flavonoids: 
implications for cardiovascular health. Can J Cardiol, 2010. 26 Suppl A: p. 17A-21A. 
37 
 
51. Crozier, A., D. Del Rio, and M.N. Clifford, Bioavailability of dietary flavonoids 
and phenolic compounds. Mol Aspects Med, 2010. 31(6): p. 446-67. 
52. Mulvihill, E.E., et al., Nobiletin attenuates VLDL overproduction, dyslipidemia, 
and atherosclerosis in mice with diet-induced insulin resistance. Diabetes, 2011. 60(5): p. 
1446-57. 
53. He, B., et al., The Small Molecule Nobiletin Targets the Molecular Oscillator to 
Enhance Circadian Rhythms and Protect against Metabolic Syndrome. Cell Metab, 2016. 
23(4): p. 610-21. 
54. Qi, G., et al., Nobiletin protects against insulin resistance and disorders of lipid 
metabolism by reprogramming of circadian clock in hepatocytes. Biochim Biophys Acta 
Mol Cell Biol Lipids, 2018. 1863(6): p. 549-562. 
55. Li, R.W., et al., Citrus polymethoxylated flavones improve lipid and glucose 
homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. 
Life Sci, 2006. 79(4): p. 365-73. 
56. Burke, A.C., et al., Intervention with citrus flavonoids reverses obesity and 
improves metabolic syndrome and atherosclerosis in obese Ldlr(-/-) mice. J Lipid Res, 
2018. 59(9): p. 1714-1728. 
57. Emini Veseli, B., et al., Animal models of atherosclerosis. Eur J Pharmacol, 2017. 
816: p. 3-13. 
58. Kennedy, A.J., et al., Mouse models of the metabolic syndrome. Dis Model Mech, 
2010. 3(3-4): p. 156-66. 
59. Wu, L. and K.G. Parhofer, Diabetic dyslipidemia. Metabolism, 2014. 63(12): p. 
1469-79. 
60. Xiao, C., et al., Pharmacological Targeting of the Atherogenic Dyslipidemia 
Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. 
Diabetes, 2016. 65(7): p. 1767-78. 
38 
 
Chapter 2  
2 Nobiletin corrects intestinal insulin resistance and lipid 
metabolism in Ldlr-/- mice fed a high-fat diet 
2.1 Introduction 
Excess energy intake relative to energy expenditure drives the abnormalities that 
encompass the metabolic syndrome (MetS) - namely, obesity, insulin resistance, 
atherogenic dyslipidemia and hypertension [1]. Insulin resistance, a central component of 
MetS, is characterized by a decrease in insulin-stimulated glucose transport and 
metabolism in adipocytes and skeletal muscle as well as impaired suppression of glucose 
output, causing hyperglycemia. Furthermore, hyperinsulinemia associated with insulin 
resistance causes increases in triglyceride (TG) synthesis from de novo lipogenesis. As a 
result, insulin resistance is associated with increased hepatic VLDL production, HDL-
cholesterol is decreased and LDL-cholesterol is increased [2].  
Although insulin resistance has been well documented in liver, it is possible that this also 
occurs in the intestine in insulin resistant states. Emerging evidence demonstrates that 
insulin-resistant subjects also overproduce triglyceride-rich, ApoB 48-containing 
chylomicrons, resulting in increased postprandial lipemia [3, 4]. Postprandial 
hypertriglyceridemia is now recognized to play a prominent role in the pathogenesis of 
atherosclerosis [2, 5], highlighting the importance of understanding the molecular 
regulation of intestinal lipoprotein metabolism. Furthermore, there is a growing need for 
novel therapeutics that target intestinal lipid metabolism. 
 Intestinal enterocytes are responsible for absorbing and packaging lipids for 
storage in cytoplasmic lipid droplets (CLD) or in chylomicrons for distribution 
throughout the body. Furthermore, the number and size of CLDs in mouse enterocytes 
correspond to the fat content of the diet [6]. The presence of nutrients in the small 
intestine stimulates intestinal L-cells to secrete hormones glucagon-like peptides 1 and 2 
(GLP-1 and GLP-2) [7]. These two hormones have opposing effects on metabolism, 
where GLP-1 lowers glycemia and post-prandial plasma chylomicron triglycerides [8] 
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and GLP-2 increases intestinal fat absorption and chylomicron-triglyceride secretion into 
plasma [9]. As such, both have been exploited pharmacologically: GLP-1 receptor (GLP-
1R) agonists are widely used as treatments for patients with T2DM and GLP-2 receptor 
agonists have been successfully used to treat patients with short bowel syndrome [7]. 
Epidemiologically, higher intake of flavonoids correlates with lower cardiovascular risk 
[10]; nobiletin is a tangerine-derived flavonoid with significant therapeutic potential [10]. 
Supplementation of nobiletin to a high-fat, high-cholesterol (HFHC) diet in Ldlr-/- mice, 
a physiological model of MetS, prevents obesity, insulin resistance, hepatic steatosis, 
dyslipidemia and atherosclerosis, in part, through enhanced hepatic-fatty acid oxidation 
[11]. While these studies provide insight into the metabolic effects of nobiletin, they 
primarily focus on the liver, providing limited understanding of the protective role of 
nobiletin on the small intestine. Intriguingly, Ldlr-/- mice fed a HFHC diet, but not chow, 
retain lipids in the jejunum of the small intestine, even in the fasted state. The addition of 
nobiletin to the HFHC diet completely prevents this fasting jejunal lipid accumulation, 
which may be related to nobiletin-induced enhanced insulin sensitivity. Due to the 
evidence that hormonal and nutritional signals play a role in the initiation of intestinal 
lipoprotein formation [7], the purpose of these studies was to examine the metabolic 
effects of feeding both male and female mice a HFHC diet on the development of 
intestinal insulin resistance, intestinal lipid accumulation, post-prandial chylomicron 
secretion and gut peptide secretion. Moreover, the potential therapeutic effects of 
nobiletin to prevent HFHC diet-induced dysregulation of intestinal lipoprotein 
metabolism were explored. 
2.2 Materials and methods 
2.2.1 Animals and diets 
Male and female Ldlr-/- mice on a C57BL/6 background (Jackson Laboratory, Bar 
Harbor, MA), were housed in pairs in standard cages at 23˚C on a 12 h light and dark 
cycle. The animals were cared for in accordance with the Canadian Guide for the Care 
and Use of Laboratory Animals. All experimental procedures were approved by the 
Animal Care Committee at Western University (protocol # AUP-2016-057). Mice 10-12 
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weeks of age (n=16) were fed ad libitum, a purified rodent chow diet (14% of calories 
from fat, Teklad Rodent Diet 8604, Envigo, Madison WI) for 10-12 weeks. Another 
group of mice (10-12 weeks of age, n=16/group) were fed a high-fat, high cholesterol diet 
(HFHC; 42% calories from fat, 0.2% cholesterol, Teklad TD 09268, Envigo, Madison, 
WI) for 10-12 weeks. The third group of mice (10-12 weeks of age, n=16/group) were 
fed the HFHC-diet supplemented with 0.3% nobiletin (#10236-47-2, R&S PharmChem, 
Hangzhou City, China). Food intake and body weight measured weekly. Caloric intake 
was calculated as weight of food eaten (g) per day multiplied by the caloric content of 
each diet (chow 3.0 kcal/g; HFHC 4.5 kcal/g). We previously observed a taste aversion 
with nobiletin, which was mitigated by increasing the flavonoid dose by 0.1% every two 
days until 0.3% was achieved in order to prevent significant impact on food intake (data 
not shown). 
2.2.2 Blood and tissue collection 
Mice were fasted for 6 hours at the start of the light cycle prior to blood taking or 
sacrifice. Blood was collected via saphenous vein for fasting and post-gavage samples. At 
sacrifice, animals were euthanized by CO2 inhalation and blood was collected via cardiac 
puncture in syringes containing 80µL of 7% Na2-EDTA. Blood was centrifuged at 12 
000 rpm for 10 minutes at 4˚C to separate plasma, which was stored at -20˚C for further 
use. Tissue dissections were performed via midline incision. Pancreata were removed, 
weighed and fixed in 4% paraformaldehyde and paraffin-embedded for histological 
analyses. The entire small intestine (~36cm) was excised and cut in 3 pieces at a 1:3:2 
ratio (duodenum:jejunum:ileum). Pieces were flushed with 0.5 mM sodium taurocholate 
warmed to 37˚C, ectopic fat was removed, segments were flushed with saline at 4˚C. The 
first piece of each section of the small intestine was cut and placed in optimum cutting 
temperature (OCT) medium, frozen on dry ice and stored at -80˚C for histological 
analyses. Jejunal epithelial cells were scraped and frozen on dry ice for mRNA and lipid 
measurements. Liver, epididymal white adipose tissue (eWAT), inguinal white adipose 
tissue (iWAT) or parimentrial white adipose tissue (pWAT) were removed, weighed and 
snap-frozen in liquid N2 and stored at -80˚C. 
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2.2.3 Glucose tolerance test 
A glucose tolerance test was performed following a 6 hour fast by administering 15% 
glucose in 0.9% NaCl (1g/kg body weight) by oral gavage or i.p. injection [12]. Blood 
samples for glucose measurements (Bayer Contour Blood Glucose Monitoring System, 
Bayer Healthcare) were taken up to 120 minutes post-glucose load. Glucose tolerance 
was calculated as a delta from baseline. Blood samples for plasma insulin measurements 
(Elisa) were taken up to 60 minutes. Plasma insulin was determined in EDTA-plasma 
samples, stored at -20˚C, by mouse specific ELISA (ALPCO Diagnostics, Salem, NH: 
mouse ultrasensitive ELISA #80-INSMSU-E01). 
2.2.4 Postprandial triglyceridemic response 
Food was removed for 6 h at the start of the light cycle, mice were injected with 
poloxamer-407 (i.p.) to block catabolism of lipoproteins. 30 min later, a 200 µl olive oil 
gavage was administered and blood collected at baseline and up to 4 h post-gavage. No 
food was available during the time course. 
2.2.5 Tissue lipids 
Intestinal segments and liver lipids were extracted from ~80-100mg of tissue obtained at 
sacrifice using the method of Folch et al, from samples stored at -80˚C, as described 
previously [13, 14]. For quantification of TG, FC and TC in tissues, [3H] Cholesterol 
oleate (Amersham Canada Ltd, Oakville, ON, Canada) were added to assess recovery. 
Samples and standards were dried under N2, and a 1% Triton X-10 solution in 
chloroform was added and left at room temperature for 1 hour to solubilize. Samples and 
standards were dried under N2, followed by the addition of deionized water and 
incubation at 37˚C for 15 minutes. Samples were analyzed using enzymatic reagents for 
triglyceride (Roche Diagnostics: Triglyceride/glycerol blanked, #11877771 216), total 
cholesterol (WAKO Diagnostics: Cholesterol E (CHOD-DAOS method) #439-17501) 
and free cholesterol (WAKO Diagnostics: Free cholesterol (CHOD-DAOS method) 
#439-17501). Cholesteryl ester was determined as the difference between total 
cholesterol and free cholesterol. 
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2.2.6 Plasma measurements 
Plasma triglyceride and total cholesterol was measured on Cobas Mira S autoanalyzer 
(Roche Diagnostics, Laval, Canada) using calibrators and controls from Roche 
Diagnostics [12]. Enzymatic reagents for triglyceride (Roche Diagnostics: 
triglyceride/glycerol blanked #11877771 216) and cholesterol (Roche Diagnostics: 
Cholesterol CHOD-PAP #11491458-216) were used. Plasma insulin (ALPCO 
Diagnostics, Salem, NH: mouse ultrasensitive ELISA #80-INSMSU-E01) was 
determined in EDTA-plasma samples stored at -80˚C. For measurement of active GLP-1 
(Mesoscale 150JVC-1) and active GIP (Crystal Chem) blood was mixed with 10% TED 
(5,000 KIU/mL Trasylol, 1.2 mg/mL EDTA, 0.1 nmol/L Diprotin A) and plasma stored 
at -80˚C until the assay was performed. DPP-4 activity was assessed using a fluorometric 
assay (substrate: 10 mM H-Gly-Pro_AMC HBr (Bachem#I-1225), standard: AMC 
(Bachem #Q-1025) using 10 µL of plasma (no TED).   
Fresh-EDTA plasma (50µL) was separated by fast protein liquid chromatography (FPLC) 
using an AKTA purifier and a Superose 6 column [13]. Constant flow rate of 0.4mL/min 
was used to collect 500µL fractions. An aliquot of each fraction was used to measure 
cholesterol and triglycerides enzymatically in both standards and samples on a microtitre 
plate with added enzymatic reagents (Triglyceride: Roche Diagnostics, 
triglycerides/glycerol blanked #11877771 216 and total cholesterol: WAKO Diagnostics, 
Richmond, VA, Cholesterol E: (CHOD-DAOS method) #439-17501). 
2.2.7 Limulus amebocyte lysate assay 
Plasma lipopolysaccharide (LPS) concentration was determined using a commercial kit 
(GenScript) following the manufacturer's instructions. Briefly, samples (stored at -20 ˚C) 
were diluted 1/10 with endotoxin-free water, heated for 10 min at 70 ˚C to minimize 
background by contaminating proteins. Limulus amebocyte lysate assay (LAL) reagents 
were added to samples and standards, which were then loaded onto a microtitre plate. 
Following a 45 min incubation at 37 ˚C, absorbance was read at 545 nm. 
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2.2.8 Plasma ultracentrifugation 
For fasting samples, plasma of body-weight matched mice were pooled. Lipoproteins 
were separated from fresh plasma by ultracentrifugation in a Beckman TLA-120.2 
ultracentrifuge using Quick seal tubes #344625 (Beckman Coulter, Mississauga, ON). 
Plasma was spun at 17,000 rpm, 12oC, for 30 minutes to isolate the chylomicron fraction 
(intestinal contribution). Following chylomicron removal, the subnatant was centrifuged 
in a new tube at 40,000 rpm, 12oC for 2 hours to isolate the VLDL fraction (intestinal 
and liver contribution). 
2.2.9 Plasma immunoblotting 
Plasma was diluted 3200-fold in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2PO4, 1.8 mM KH2PO4) containing 1:100 protease (Sigma P8340) and 
phosphatase inhibitors (Sigma P5726). Chylomicron and VLDL fractions of plasma were 
diluted 32-fold in PBS containing the same protease and phosphatase 1:100 cocktail. 
Samples were run in duplicate on 10% SDS-PAGE gels (BioRad #456-1086) and 
transferred in a nitrocellulose membrane. Membranes were blocked and incubated with 
primary antibodies goat anti-human apoB diluted 1:200 (Midland Bioproducts 
Corporation #71307) and goat anti-albumin diluted 1:20 000. Membranes were washed 
and incubated with the secondary antibody IRDye® 800CW Donkey anti-Goat IgG 
(H+L) #925-32214 (LI-COR Biosciences, Lincoln, NE) . Imaging and quantitation of 
membranes was performed using the LI-COR Odyssey Fc (LI-COR Biosciences) and the 
LI-COR Image Studio Software 5.0. Plasma apoB48 signal was normalized to albumin 
and expressed as a fold change from the signal of a chow-fed mouse 2 hours post-olive 
oil gavage. 
2.2.10 Tissue immunoblotting 
Frozen jejunal and liver samples were homogenized with a wheaton grinder attached to a 
power drill in RIPA buffer (Sigma R0278) containing 1:100 protease inhibitors (Sigma 
P8340) and phosphatase inhibitors (Sigma P5726) and 1 mM DTT. Lysates were 
collected following sonication and centrifugation and protein concentration determination 
was performed by Lowry assay as described previously [15]. For mTORC1, Akt and 
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FoxO1 proteins, 12.5 µg, 6.25 µg and 50µg of protein were loaded per lane, respectively, 
on a 4-15% SDS-PAGE gel (BioRad Canada, Mississauga, ON, #456-1086). In addition 
to using molecular weight markers, a liver lysate was run next to the jejunal lysate for 
band identification, as the concentrations of signalling molecules are higher in liver. 
Proteins were transferred to a nitrocellulose membrane and incubated with primary 
antibodies from Cell Signalling (Danvers, MA): total mTOR (#4517), Ser2448 phospho-
mTOR (#2971), total AkT (#9272), Ser-473 phospho-AkT (#4051), total FoxO1 
(#97635) and Ser256 phospho-FoxO1 (#9461). Membranes were washed and incubated 
with a secondary antibody from Cell Signaling; anti-Rabbit IgG horseradish peroxidase 
(HRP)-linked #7074 or anti-Mouse rabbit IgG HRP-linked #7076. Detection was 
determined using enhanced chemiluminescence reagent (Roche Diagnostics) and 
quantification performed using an Imaging Densitometer (GS-700; Bio-Rad Laboratories, 
Mississauga, ON). 
2.2.11 Jejunal fatty acid synthesis 
Fatty acid synthesis was measured following an (i.p) injection of [1-14C]-acetate 
(Amersham, GE Healthcare, UK). Briefly, mice were injected with 20 µCi of acetic acid 
and sacrificed 30 minutes later. Jejunum (500 mg) were extracted in chloroform:methanol 
and incorporation of 1-14C acetic acid into fatty acid was performed as described 
previously [15]. 
2.2.12 Jejunal triglyceride synthesis 
Triglyceride synthesis was measured by incubating jejunal homogenates with an ACAT 
inhibitor (DuP -128) and [14C]oleoyl-CoA (Amersham GE). The reaction was stopped 
after 3 minutes by the addition of chloroform-methanol (2:1) and [3H]cholesteryl oleate 
(Amersham GE) was used as an internal standard. Lipid extracts were dissolved and 
spotted on TLC plates. Spots were developed in petroleum ether/diethyl-ether/acetic acid 
(84:15:1) and identified using iodine vapour. The radioactivity in cholesteryl oleate and 
triolein spots was determined by liquid scintillation counting [16]. 
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2.2.13 Jejunal beta-oxidation 
Whole jejunum was excised from euthanized mice and placed in homogenizing buffer 
(RIPA) on ice. Jejunum was flushed with 4˚C PBS and sucrose-Tris-EDTA buffer at 4˚C 
and ectopic fat was removed. Jejunum was threaded onto a zip-tie and opened 
longitudinally onto a glass platform on ice and mucosa was scraped using a cover slip. 
Mucosa was homogenized in 0.1 M phosphate buffer, pH 7.2 containing 0.25 M sucrose, 
10 mM Tris-HCl, 1 mM EDTA, 1 mM dithiothreitol, and 250 µL of protease inhibitor 
(Sigma-Aldrich #P8340). Homogenates were gently vortexed and centrifuged for 20 
seconds, and a small aliquot was used for protein determination by the Lowry method 
[16]. 50 µL of homogenate was incubated in 0.1 M phosphate buffer, pH 7.2, containing 
15 mM Tris malonate, 10 mM MgCl2, 0.5 M DTT, 1 mM carnitine, 0.05 mM coenzyme-
A, 5 mM ATP, 2 µCi of [1-14C]palmitic acid (PerkinElmer: # NEC075H250UC)/mM 
and 150 µM unlabeled palmitic acid complexed with 3% fatty acid-free BSA at 37˚C for 
1 hour. Reactions were transferred to a collection tube with a filter paper-lined cap 
containing 200 µL of 1M perchloric acid and 20 µL of benzethonium chloride for 1 hour. 
14CO2 in the filter pads were measured by liquid scintillation counting. 
2.2.14 Gene expression 
RNA was isolated from whole jejunum or jejunal mucosa using Trizol reagent (Life 
Technologies, Mississauga, Ontario, Canada). Reverse transcription of 1 µg total RNA 
was performed using the High Capacity Reverse Transcription kit (Applied Biosystems, 
ABI, Streetsville, CA) to yield cDNA. Specific mRNA abundances were measured by 
quantitative real-time PCR (qRT-PCR) on an ABI ViiA 7 Sequence Detection System 
(ABI) according to the manufacturer's instructions. In the jejunum, mRNA quantification 
for Srebf1c, Plin2, Atgl, Mttp, Cd36, Dgat2 was determined. 10 ng samples of cDNA 
were assayed in triplicate in 10 µL reactions using a standard curve qRT-PCR protocol to 
calculate specific mRNA concentrations. Expression levels for each gene were 
normalized to Gapdh expression in jejunum or mucosa. With the exception of Srebf1c, all 
primer and probe sets used were purchased as TaqMan Assays (ABI). The probe and 
primer sequences for Srebf1c were designed from the known murine Srebf1  locus to 
determine splice junctions. The intervening intronic sequence was removed and primers 
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and probe were designed from the resultant Srebf1c exon1c-exon2 sequence using Primer 
Express 2.0 software (ABI). Primers were obtained from Sigma-Genosys and the probes 
labeled 5' with 6-carboxyfluorescein (FAM) and 3' with the quencher MGB® were from 
ABI. TaqMan assay for mouse Srebf1c: Forward primer: CAGGCCCGGGAAGTCACT' 
Reverse primer: GACCACGGAGCATGGATT; Probe: FAM-
ATTTGAAGACATGCTCCA-MGB®. 
2.2.15 Tissue histology and immunohistochemistry 
Frozen sections (5-10 per jejunum and ileum, 8µm) 100 µm apart were prepared using a 
Leica CM 3050S cryostat. Sections from fasted mice were stained with oil red-O and 
counterstained with hematoxylin (Sigma-Aldrich). Photomicrographs were obtained 
using an Olympus BX51 microscope (Olympus Canada, Richmond Hill, Canada). 
Pancreata were fixed in 4% paraformaldehyde for 24 hours, processed, embedded in 
paraffin, and sectioned on a Micron HM335E microtome (Thermo Fisher Scientific). 
Pancreas sections (2-3 sections per mouse, >150 µm apart) were blocked with mouse on 
mouse (M.O.M) blocking reagent (BMK-2202), incubated with 1:500 mouse anti-mouse 
insulin antibody (Sigma I2018) and detected with peroxidase-labeled anti-mouse 
antibody (Vector Labs, Burlingame CA, USA). A minimum of 10 insulin-positive cells 
was required for islet enumeration [17]. Photomicrographs of whole tissue sections were 
obtained using a Leica Aperio AT2 slide scanner and villi-length measurements were 
performed using ImageScope. 
2.2.16 Transmission electron microscopy (TEM) 
Mice were anesthetised using inhaled CO2 following a 6-hour fast or 2-hours after a 200 
µL oral olive oil gavage. Jejunum was removed and flushed with sodium taurocholate 
warmed to 37˚C, ectopic fat was removed and segments were then flushed with 4˚C 
saline. Small pieces of the jejunum were fixed in freshly prepared room temperature 1 % 
paraformaldehyde and 1 % glutaraldehyde in 0.1M/L phosphate-buffered saline. Samples 
were stored in the primary fixative at 4˚C for several days. Sample preparation, 
sectioning, staining and visualization was performed at the UWO Biotron by Stephen 
Hearn. After rinsing with distilled water, the tissue was pot-fixed in 1 % osmium 
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tetroxide in distilled water for 1 hour, then dehydrated in a graded series of ethanol to 
remove all water and immersed in 100% acetone. The tissue was then infiltrated for 1 
hour with agitation with 50% epon-araldite resin (Electron Microscopy Sciences, Hatfield 
PA) in 100% acetone, followed by infiltration with 100% epon-araldite resin for 2 hours 
with agitation. The samples were then transferred to embedding molds with fresh resin 
and polymerized overnight in a 60˚C oven. Tissues in the resin blocks Thick sections (0.5 
µm) were sliced with a Reichert Ultracut ultramicrotome and stained with 1% toludine 
blue and examined by light microscopy to confirm tissue orientation. Ultrathin sections 
(90 nm) were stained for 1 minute with Reynolds lead citrate. Images were acquired on a 
Philips 420 transmission electron microscope equipped with a side mount AMT 4K 
megapixel XR41S-B camera (Woburn, MA). The identification of TG in CLDs was 
based on previously published studies [6, 18]. 
2.2.17 Glucagon-like peptide 2 receptor antagonist, GLP-2 (3-33), 
treatment 
Synthetic mouse GLP-2 (3-33) was purchased from Chi Scientific (Maynard, MA). The 
purity (>0.95) and correctness of the structure was confirmed by mass spectrometry and 
HPLC analysis. GLP-2 (3-33) dissolved in PBS or PBS (vehicle) were injected 
subcutaneously into mice at 11am daily for 14 days following a 10-week feeding period. 
2.2.18 Statistical analysis 
Data is presented as mean ± SEM. Statistical analyses were performed using Prism One-
way ANOVA with post-hoc Tukey's test for differences between groups at the same 
experimental time points except in the case of body weight, which was measured over 
time and a 2-way repeated measures ANOVA with post-hoc Tukey's test was used. 
Different letters indicated significant differences between diet groups at a particular time 
point whereas symbols indicated significant differences from baseline (delta, Δ) between 
diet groups. Significance thresholds were P values less than 0.05. An unpaired t-test was 
used to test for differences in the fasting-refeeding studies and significant differences 




2.3.1 Nobiletin prevents high-fat, high-cholesterol (HFHC)-diet 
induced weight gain 
We employed a mouse model of the metabolic syndrome, namely Ldlr-/- mice fed a chow, 
a HFHC diet, or a HFHC diet supplemented with 0.3% nobiletin (w/w) for ten weeks. 
Body weight rapidly increased in mice fed the HFHC diet, which was prevented with the 
supplementation of nobiletin to the same diet (Figure 2.1A). The prevention of HFHC-
induced weight gain was independent of caloric intake (Figure 2.1B&C). 
2.3.2 Nobiletin prevents HFHC-diet induced fasting jejunal lipid 
accumulation 
Previously, our laboratory has shown that significant levels of triglyceride (TG) mass 
remained in the intestine of HFD-fed mice following a 6 hour fast but not in mice fed the 
same HFD diet supplemented with nobiletin [11]. Furthermore, the absorption of dietary 
lipid did not differ between HFD-fed and HFD-plus nobiletin-fed mice [11]. To 
determine a time course estimate for intestinal TG excursion, jejunal TG was quantified 
from the beginning of the light cycle throughout the course of a 9-hr fast (Figure 2-2A). 
The HFHC-fed mice have significantly elevated jejunal TG at the beginning of the light 
cycle, which is normalized with the addition of nobiletin to the same HFHC diet. As the 
fasting time increased, the amounts of jejunal TG mass in HFHC-fed mice eventually fall 
to those of chow and HFHC + nobiletin levels, indicative of intestinal-TG excursion into 
plasma. However, a significantly elevated TG mass remained in the jejunum of HFHC-
fed mice after a 6-hour fast. Jejunal TG mass following a 6-hr fast was further quantified 
in another set of mice. HFHC-fed mice had a 3-fold increase in jejunal TG and a 2.5-fold 
increase in jejunal cholesteryl ester (CE), which were both completely corrected by the 
addition of nobiletin to the HFHC diet (Figure 2-2B&C). Neutral lipid accumulation in 
jejunal sections of the small intestine of fasted mice was visualized using Oil Red O 
staining. In keeping with the biochemical analysis, greater staining was observed in the 
HFHC-fed mice compared to chow-fed mice. The addition of nobiletin to the HFHC diet 









Figure 2-1 Nobiletin prevents HFHC diet-induced weight gain. 
 Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A) 
Structure of nobiletin. (B) Body weight gain. (C) Caloric intake expressed as kcal/g body 
weight/day. Values are the mean ± SEM, * indicates significant differences in body 
weight between HFHC-fed and HFHC + nobiletin-fed mice by repeated measures Two-























































Figure 2-2 Nobiletin prevents HFHC-diet induced fasting jejunal lipid 
accumulation.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A) 
Mice were sacrificed at the beginning of the light cycle (fed state) and after 3,6, and 9 
hours (n= 4/time point). In a separate experiment, mice were fasted for 6 hours (n=12-
14/group). (B) Jejunal TG and (C) CE determined by lipid extraction. Data represents 
mean±SEM. * and different letters are statistically different by ANOVA with post-hoc 
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Figure 2-3 Nobiletin prevents HFHC-diet induced jejunal lipid accumulation 
following a 6-hour fast.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were sacrificed following a 6 hours (n=12-14/group). Representative frozen sections (8 
µm) of jejunal segments, prepared using a cryostat, stained with Oil Red O and 
















To investigate subcellular lipid pools within the enterocytes of 6-hr fasted HFHC and 
HFHC + nobiletin-fed mice, ultrastructural analyses were performed using transmission 
electron microscopy (TEM). In the HFHC-fed mouse, lipids were observed in various 
locations of the enterocyte (Figure 2-4A). Nobiletin treatment appeared to localize lipids 
to the Golgi (Figure 3B). In the HFHC-fed mouse, lipids were observed in cytoplasmic 
lipid droplets (CLDs) (Figure 2-4C), endoplasmic reticulum (Figure 2-4E). Lipid storage 
in CLDs and the ER appeared to be less frequent in nobiletin treated mice (Figure 2-4D). 
Together, this suggests that nobiletin more efficiently secretes lipids from dietary and 
endogenous sources. Finally, we observed striking differences in presence and 
morphology of other organelles between HFHC- and HFHC + nobiletin-fed mice. We 
observed either round and swollen mitochondria, lysosomal or autophagosomal 
organelles in the HFHC-fed mouse (Figure 2-4E). Nobiletin maintained normal 









Figure 2-4 Subcellular lipid pools within the enterocytes of 6-hr fasted HFHC and 
nobiletin-treated mice.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were sacrificed following a 6 hour fast (n=1/group). Representative ultrathin sections (90 
nm) of jejunal segments, prepared using an ultramicrotome, stained with lead citrate and 
visualized in a Philips 420 transmission electron microscope.  
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2.3.3 Intestinal insulin signaling 
2.3.3.1 Nobiletin normalizes plasma insulin and plasma free fatty 
acids in response to a fasting, re-feeding protocol 
In the setting of insulin resistance, plasma free fatty acids (FFA) released from adipose 
tissue can accumulate in peripheral tissues, propagate insulin resistance and serve as 
substrates for TG synthesis and lipid storage [19, 20]. To determine if changes in insulin 
sensitivity contribute to fasting intestinal lipid accumulation in HFHC-fed mice, we 
assessed intestinal insulin signaling in response to a physiological release of insulin using 
a fasting-re-feeding protocol. Following a 6-hour fast, half of the mice were sacrificed in 
the fasted state (low plasma insulin), while the remaining half were re-fed their respective 
diets for 2 hours before sacrifice to induce a physiological release of insulin. HFHC-fed 
mice displayed a 4-fold increase in fasting plasma insulin, which was corrected by 
nobiletin (Figure 2-5A). Fasting plasma free fatty acids were significantly reduced by 
nobiletin compared to HFHC-fed mice (Figure 2-5B). All three groups displayed a 
significant reduction in plasma free fatty acids in response to re-feeding, however, 
HFHC-fed mice failed to fully suppress lipolysis compared to both HFHC + nobiletin-fed 










Figure 2-5 Nobiletin reduces fasting hyperinsulinemia and restores suppression of 
triglyceride lipolysis.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours 
prior to sacrifice (Refed). Plasma (A) insulin and (B) free fatty acids (n=7-8/group). 
Values are the mean ± SEM. Different letters indicate difference between diets in the 
fasted (uppercase) and re-fed state (lowercase) between diet groups by ANOVA with 
post-hoc Tukey test, P<0.05. * indicate significant differences between fasted and refed 
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2.3.3.2 Nobiletin improves intestinal insulin signaling 
To determine if the hyperinsulinemia and elevated plasma FFA detected in HFHC-fed 
mice propagated insulin resistance to the intestine, we measured phosphorylation of 
insulin signaling molecules in jejunal lysates of 6-hour fasted mice and 6-hour fasted and 
2-hour re-fed mice as a measure of intestinal insulin sensitivity. In response to re-feeding, 
Akt phosphorylation increased in all three groups (Figure 2-6). FoxO1 phosphorylation 
was not significantly different at fasting between diet groups. In response to re-feeding, 
FoxO1 phosphorylation failed to increase in the HFHC-fed mice, indicating insulin 
resistance. Nobiletin significantly increased FoxO1 phosphorylation in response to re-
feeding (Figure 2-7). The fasting hyperinsulinemia displayed in HFHC-fed mice 
appeared to be drive a small, but not significant, trend for increase in fasting mTORC1 
phosphorylation, which increased further, but not significantly, in response to re-feeding 
(Figure 2-8). The correction of fasting plasma insulin by nobiletin caused a small, but not 
significant reduction in fasting and re-fed mTORC1 phosphorylation (Figure 2-8). We 
measured the expression of the downstream effector of mTORC1 phosphorylation, 
namely Srebf1c, the master regulator of de novo lipogenesis. Despite the non-significant 
changes in mTORC1 phosphorylation, Srebf1c expression in HFHC-fed mice was 
significantly increased in the fasted state and increased even further following re-feeding. 
Nobiletin corrected Srebf1c expression in the fasted state and significantly attenuated its 









Figure 2-6 Nobiletin corrects dysregulated intestinal insulin signaling.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours 
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by 
immunoblotting jejunal lysates. (A) Ratio of phosphorylated Akt to total Akt protein 
(n=6-8/group) and (B) Representative gel image. Values are the mean ± SEM. Different 
letters indicate difference between diets in the fasted (uppercase) and re-fed state 
(lowercase) between diet groups by ANOVA with post-hoc Tukey test, P<0.05. * 
indicate significant differences between fasted and refed mice within the same diet group 
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Figure 2-7 Nobiletin corrects dysregulated intestinal insulin signaling.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours 
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by 
immunoblotting jejunal lysates. (A) Ratio of phosphorylated FoxO1 to total FoxO1 
protein (n=6-8/group) and (B) Representative gel image. Values are the mean ± SEM. 
Different letters indicate difference between diets in the fasted (uppercase) and re-fed 
state (lowercase) between diet groups by ANOVA with post-hoc Tukey test, P<0.05. * 
indicate significant differences between fasted and refed mice within the same diet group 
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Figure 2-8 Nobiletin corrects dysregulated intestinal insulin signaling.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours 
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by 
immunoblotting jejunal lysates. (A) Ratio of phosphorylated mTORC1 to total mTORC1 
protein (n=6-8/group) and (B) Representative gel image. Values are the mean ± SEM. 
Different letters indicate difference between diets in the fasted (uppercase) and re-fed 
state (lowercase) between diet groups by ANOVA with post-hoc Tukey test, P<0.05. * 
indicate significant differences between fasted and refed mice within the same diet group 
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Figure 2-9 Nobiletin corrects dysregulated intestinal insulin signaling.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and either sacrificed (Fast) or refed their normal diets for 2 hours 
prior to sacrifice (Refed). Markers of intestinal insulin signaling were determined by 
immunoblotting of jejunal lysates. (A) Expression of jejunal Srebf1c relative to Gapdh, 
determined by qRT-PCR (n=6-8/group). Values are the mean ± SEM. Different letters 
indicate difference between diets in the fasted (uppercase) and re-fed state (lowercase) 
between diet groups by ANOVA with post-hoc Tukey test, P<0.05. * indicates 
significant differences between fasted and refed mice within the same diet group by 
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2.3.4 Nobiletin corrects intestinal de novo lipogenesis 
To determine if the aberrant intestinal insulin signaling and elevated plasma FFA 
detected in HFHC-fed mice increases fasting de novo lipogenesis, we measured de novo 
lipogenesis within the jejunum of 6 hour fasted mice ex vivo. HFHC-fed mice had 
increased jejunal fatty acid synthesis (Figure 2-10A) and triglyceride synthesis (Figure 2-
10B), both of which were corrected by nobiletin. Despite marked improvements in 
intestinal mitochondrial morphology observed by TEM (Figure 2-4E&F), the capacity for 
jejunal fatty acid oxidation was significantly increased in mice fed the HFHC alone and 
only a trend for further increase was observed with nobiletin treatment (Figure 2-10C). 
This equivalent potential to oxidize fat suggests that the reduced fasting intestinal lipid 
accumulation in nobiletin-treated mice is not due to an increased capacity for fatty acid 
oxidation.  
 
Collectively, these results indicate that addition of nobiletin to the HFHC diet prevents 
the induction of Srebf1c expression resulting in attenuated intestinal de novo fatty acid 
synthesis thereby limiting excess TG substrate for intestinal lipid storage. However, other 
mechanisms including altered dynamics of TG storage and subsequent excursion of 









Figure 2-10 Nobiletin prevents fasting de novo lipogenesis.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks.  (A) 
Jejunal fatty acid synthesis was determined by injecting 14C-acetic acid (i.p.) following a 
6 hour fast and killing the mice 1 hour later. 14C-acetic acid incorporation into fatty acids 
from jejunal lipid extracts following saponification (n=7-8/group). (B) Jejunal 
triglyceride synthesis was determined by 14C-oleate incorporation ex vivo (n=7/group). 
(C) Jejunal fatty acid oxidation was determined by 14C-Palmitate conversion to 14CO2 in 
mucosal scrapings (n=14-15/group). Values are the mean ± SEM, different letters are 
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2.3.5 Postprandial intestinal glucose metabolism 
2.3.5.1 Nobiletin prevents HFHC-diet induced hyperinsulinemia in 
response to a glucose challenge 
 
Previously, our lab reported that an intraperitoneal (i.p.) glucose tolerance test (GTT) in 
nobiletin treated HFHC-fed Ldlr-/- mice revealed improved glucose tolerance, indicative 
of improved whole body insulin sensitivity [13]. However, this route of glucose 
administration excludes the incretin response that is known to potentiate glucose-
stimulated insulin secretion [7, 21]. Therefore, we further explored the HFHC diet-
induced dysregulation of hormonal signaling within the gut on glucose metabolism and 
the potential correction by nobiletin. 
Following a 6-hour fast, we challenged the mice with a glucose load delivered either i.p., 
which bypasses the intestine and thus prevents incretin release, or by oral gavage. 
Nobiletin improved the impaired glucose tolerance observed in HFHC-fed mice 
following a glucose load administered i.p. (Figure 2-11A) and by oral-gavage (Figure 2-
11B). The glucose challenge delivered i.p. caused a 60-fold increase in plasma insulin in 
HFHC mice after 15 minutes, which was decreased after 30 minutes, but remained high 
throughout the course of the experiment (Figure 2-12A). HFHC + nobiletin-fed mice 
exhibited less than a 20-fold increase in plasma insulin compared to chow after 15 









Figure 2-11 Nobiletin improves oral glucose tolerance.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and blood was sampled before and every 15 minutes after a 
glucose load for blood glucose and plasma insulin measurements. Half of the mice 
received an intraperitoneal glucose tolerance test (IPGTT) and the other half received the 
glucose challenge by oral gavage (OGTT) (1g/kg body weight). Blood glucose was 
measured by glucometer. (A) IPGTT and (B) OGTT. Glucose utilization was determined 
as the area under the curve (AUC). Values are the mean AUC ± SEM. Different letters 
are statistically different groups by ANOVA with post-hoc Tukey test, P<0.05.  
 
  

















































































When the glucose load was administered orally, the HFHC displayed a 200-fold increase 
in plasma insulin, which was completely normalized by nobiletin (Figure 2-12B). The 
hyperinsulinemia displayed by the HFHC mice in both GTTs was significantly elevated 
compared to chow and HFHC + nobiletin as assed by the areas under the plasma insulin 
curves (Figure 2-12C). Calculation of the plasma glucose to insulin ratio at 15 minutes 
following both GTTs revealed more insulin was secreted following the oral GTT for the 
same increase in blood glucose (Figure 2-12D). However, HFHC-fed mice secrete 
significantly more insulin per mmol/L of blood glucose 15 minutes after the glucose 
challenge, especially following oral glucose challenge (Figure 2-12D). This demonstrated 
the incretin effect following oral glucose administration and suggests that HFHC-fed 









Figure 2-12 Nobiletin prevents hyperinsulinemia during a glucose challenge.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and blood was sampled before and every 15 minutes after a 
glucose load for blood glucose and plasma insulin measurements. Half of the mice 
received an intraperitoneal glucose tolerance test (IPGTT) and the other half received the 
glucose challenge by oral gavage (OGTT) (1g/kg body weight). Plasma insulin was 
measured by enzyme-linked immunosorbent assay. (A) Plasma insulin throughout the 
course of the IPGTT and (B) the OGTT. (C) Plasma insulin secretion determined as the 
AUC. (D) Glucose:insulin ratio 15 minutes post-glucose load. Values are the mean ± 
SEM. Statistical difference between groups for the IPGTT are indicated by different 
uppercase letters and differences between groups for the OGTT are indicated by 
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2.3.5.2 Plasma incretin levels in response to an oral glucose 
challenge 
GLP-1 and GIP are secreted from intestinal L-cells and K-cells, respectively, in response 
to nutrients [7]. Furthermore, they potentiate glucose-stimulated insulin secretion and are 
both subject to degradation by DPP4 [7]. We measured fasting DPP4 as well as fasting 
and post-oral gavage of glucose (at 15 min.) plasma insulin, GLP-1 and GIP to determine 
if the prevention of hyperinsulinemia by nobiletin was related to changes in incretin 
release (Figure 2-13&2-14). Fasting plasma DPP4 activity was significantly increased in 
HFHC-fed mice and in HFHC + nobiletin-fed mice (Figure 2-13A). Fasting plasma GLP-
1 in HFHC-fed mice were at the same concentration as that in chow-fed mice (Figure 2-
13B). In nobiletin treated mice, however, fasting plasma GLP-1 was significantly 
increased (Figure 2-13B). There was no observable change in plasma GLP-1 15 minutes 
after the oral glucose challenge in any of the diet groups (Figure 2-13B). The 
hyperinsulinemia observed at fasting and 15 minutes after the oral glucose challenge in 
HFHC-fed mice was associated with increased levels of fasting and post-glucose gavage 
plasma GIP (Figure 2-14). Nobiletin normalized fasting and post-gavage plasma GIP 
(Figure 2-14). Collectively, these results demonstrated the influence of HFHC-feeding on 
the incretin response to glucose. The increased plasma GLP-1, but not GIP levels, in 
nobiletin-treated mice compared to chow and HFHC was surprising considering the 
elevated fasting DPP4 activity, suggesting that endogenous GLP-1 secretion is a potential 










Figure 2-13 Plasma incretin levels following an oral glucose challenge. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and blood was sampled before and at 15 minutes after an oral 
glucose challenge (1g/kg body weight). DPP4 activity was determined by fluorometric 
assay. Plasma insulin was measured by enzyme-linked immunosorbent assay. Active 
plasma GLP-1 was measured by Mesoscale. (A) Fasting plasma DPP4 activity. Fasting 
(0) and 15 min (15) post-OGTT (B) plasma insulin and (C) GLP-1 measurements. Values 
are the mean ± SEM. Statistical difference between groups at fasting are indicated by 
different uppercase letters, differences between groups 15 min post-gavage are indicated 
by different lowercase letters and differences between the delta (15min-0hr) from 
baseline in each group are indicated by different symbols by ANOVA with post-hoc 
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Figure 2-14 Plasma GIP levels following an oral glucose challenge. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and blood was sampled before and at 15 minutes after an oral 
glucose challenge (1g/kg body weight). Active plasma GIP was measured by Mesoscale. 
(A) Fasting (0) and 15 min (15) post-OGTT plasma GIP measurements. Values are the 
mean ± SEM. Statistical difference between groups at fasting are indicated by different 
uppercase letters, differences between groups 15 min post-gavage are indicated by 
different lowercase letters and differences between the delta (15min-0hr) from baseline in 
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2.3.5.3 Nobiletin prevents HFHC-diet induced increase in β-cell 
mass 
Previous studies have determined that prolonged high-fat feeding induces β-cell 
proliferation and increased β-cell mass [22]. Interestingly, β-cell proliferation has been 
shown to occur as early as three days following high-fat feeding and therefore prior to 
insulin resistance [22]. To determine if the prevention of HFHC-diet induced 
hyperinsulinemia by nobiletin was due to a change in stored insulin, we quantified β-cell 
mass and the number of islets in pancreata of 6 hour-fasted mice. HFHC-feeding 
increased the size of insulin-positive islets (Figure 2-15 representative pictures). 
Nobiletin significantly reduced β-cell mass compared to HFHC-fed mice (Figure 2-16) 
while islet number and pancreas weight did not significantly differ between diet groups 
(Figure 2-16B&C).  
Collectively, these results indicated that addition of nobiletin to the HFHC diet prevented 
β-cell mass expansion and aberrant GIP responses to oral glucose resulting in a an 
attenuation of fasting and postprandial hyperinsulinemia. Moreover, they provide further 
evidence that intestinal hormones contribute to metabolic dysregulation in HFHC-fed 













Figure 2-15 Nobiletin prevents HFHC-diet induced β-cell mass expansion. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were sacrificed following a 6 hour fast. (A) Representative paraffin sections (5 µm) of 
pancreas, prepared using a microtome, immunostained for insulin and counterstained 
with hematoxylin (Scale bar = 3 mm). (B) Representative photomicrographs of insets 































Figure 2-16 Nobiletin prevents HFHC-diet induced β-cell mass expansion. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were sacrificed following a 6 hour fast. Islet number and size were quantified using a 
light microscope slide scanner counting all islets within 3 sections/mouse >150 µm apart. 
β-cell mass was calculated by β-cell area/non-islet area x pancreas weight (n=4-6/group). 
(A) β-cell mass. (B) Estimate of the total number of insulin-expressing islets per 
pancreas. (C) Pancreas weight. Values are the mean ± SEM, different letters are 
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2.3.6 Postprandial intestinal lipid metabolism 
2.3.6.1 Nobiletin prevents intestinal lipid accumulation following an 
oral-fat gavage 
Recent studies highlight that newly synthesized TG is not immediately secreted out of the 
enterocyte; rather, a considerable amount is stored in cytoplasmic lipid droplets (CLDs) 
as an overflow reservoir for later export [3]. Moreover, high-fat fed mice have been 
reported to have considerably more frequent and larger intestinal CLDs following an oral 
fat challenge compared to low fat-fed controls [23, 24]. To determine if HFHC + 
nobiletin feeding alters postprandial intestinal TG handling, we challenged mice to an 
oral gavage of olive oil (Figure 2-17A). 
 
Neutral lipid accumulation in jejunal sections of the small intestine of mice 2-hrs after the 
olive oil gavage was visualized using paraphenylendiamine staining. Punctate staining 
was observed in the intracellular space of HFHC-fed mice, however, the addition of 
nobiletin to the HFHC diet markedly attenuated neutral lipid staining (Figure 2-17). TEM 
was used to investigate subcellular lipid pools within the enterocytes of mice 2-hrs after 
the olive oil gavage. The olive oil gavage induced a striking formation of numerous large 
CLDs in all of the enterocytes of the HFHC-fed mouse (Figure 2-18A,C,E). By contrast, 
large CLDs were far less frequent with nobiletin treatment (Figure 2-18B). Rather, we 
observed smaller CLDs, likely associated with ER organelles with nobiletin treatment 
(Figure 2-18B,D,F). Similar to the fasted state, we observed round mitochondria in the 
HFHC-fed 2-hrs after the olive oil gavage, while long mitochondrial ultrastructures were 
observed with nobiletin treatment at this time point (Figure 2-18A&B). Chylomicrons 
were observed in the extracellular space, likely travelling towards the basolateral side of 
the enterocyte in mice fed the HFHC and the HFHC supplemented with nobiletin (Figure 
2-18C&D). Unlike the HFHC-fed mouse, we observed lipid-loaded ER ultrastructures 









Figure 2-17. Postprandial jejunal accumulation.  
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours, administered an olive oil gavage and sacrificed 2 hours later. (A) 
Experimental design. (B) Representative semi-thin sections (0.5 µm) of jejunal segments, 
prepared using an ultramicrotome, stained with paraphenylenediamine. Arrows indicate 
punctate staining of neutral lipid droplets.   
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Figure 2-18 Nobiletin reduces HFHC-diet induced CLD formation. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours, administered an olive oil gavage and sacrificed 2 hours later 
(n=1/group). Representative ultrathin sections (90 nm) of jejunal segments, prepared 
using an ultramicrotome, stained with lead citrate and visualized in a Philips 420 
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Additionally, we observed secretory vesicles only in the HFHC+nobiletin-fed mouse, 
once again highlighting the efficiency of lipid packaging for excursion from enterocytes 
at this time point. 
We also quantified TG mass throughout the entire length of the small intestine 2 hours 
and 4 hours following the oral-fat load containing both cold olive oil and 3H-triolein. 
Distribution of radiolabeled lipids from the olive oil gavage throughout the small 
intestine at 2 hours showed no significant difference in area under the curves between 
diet groups, indicative that there was no difference in absorption (Figure 2-19). There 
was, however, a non-significant trend for an increase in 3H-lipids, corresponding to 
gavage (lumenal) TG only, in the proximal intestine in HFHC-fed mice compared to 
chow-fed and nobiletin-treated mice whose 3H-lipid peaks were mid-jejunum (Figure 2-
19). HFHC-fed mice had elevated TG mass, corresponding to gavage TG as well as TG 
stored in lipid droplets, throughout the small intestine 2-hrs after the olive oil gavage, 
which was normalized with nobiletin treatment (Figure 2-20A). This reduced triglyceride 
area under the curve with nobiletin treatment was significant in the sections 
corresponding to the jejunum (Figure 2-20C). HFHC-fed mice had elevated TG mass 
throughout the small intestine 4-hrs after the olive oil gavage, however, reduced TG area 










Figure 2-19 Distribution of radiolabeled lipids from the olive oil gavage throughout 
the small intestine. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted (6 hours) and received oral gavage of 200 µL of olive oil containing 
[3H]triolein. Half of the mice were sacrificed at 2 hours and the other half at 4 hours post-
gavage (n=8/group/time). Whole intestine was excised and the small intestine divided 
into 12 equal segments for lipid extractions. (A) Distribution of radioactive tracer uptake 
along the small intestine axis from pylorus (proximal) to the ileocecal junction (distal) 2-
hours post-gavage and area under the curve (AUC) calculations. Values are the mean ± 
SEM, different letters are statistically different, by ANOVA with post-hoc Tukey test, 
P<0.05. N.S. indicates no significant difference.  
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Figure 2-20 Postprandial intestinal lipid metabolism. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted (6 hours) and received oral gavage of 200 µL of olive oil containing 
[3H]triolein. Half of the mice were sacrificed at 2 hours and the other half at 4 hours post-
gavage (n=8/group/time). Whole intestine was excised and the small intestine divided 
into 12 equal segments for lipid extractions. (A) TG concentration along the small 
intestine axis from pylorus (proximal) to the ileocecal junction (distal) 2-hours post-
gavage and area under the curve (AUC) calculations of (B) the entire small intestine and 
(C) the jejunal segments. Values are the mean ± SEM, different letters are statistically 
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Figure 2-21 Postprandial intestinal lipid metabolism. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted (6 hours) and received oral gavage of 200 µL of olive oil containing 
[3H]triolein. Half of the mice were sacrificed at 2 hours and the other half at 4 hours post-
gavage (n=8/group/time). Whole intestine was excised and the small intestine divided 
into 12 equal segments for lipid extractions. (A) TG concentration along the small 
intestine axis from pylorus (proximal) to the ileocecal junction (distal) 4-hours post-
gavage and area under the curve (AUC) calculations of (B) the entire small intestine and 
(C) the jejunal segments. Values are the mean ± SEM, different letters are statistically 
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2.3.6.2 Postprandial triglyceridemic response 
To determine if the decrease in postprandial intestinal TG accumulation is due to an 
increased excursion of lipid out of the intestine, we measured plasma triglyceride 
concentration every 2 hours for up to 8 hours following the same olive oil gavage. 
HFHC-fed mice are hyperlipidemic following a 6 hour fast, which is corrected by 
nobiletin (Figure 2-22A). In all three-diet groups, plasma triglyceride peaks at 2 hours 
post-gavage and returns to baseline by the 8-hour time point (Figure 2-22A). Similarly, 
fast protein liquid chromatography (FPLC) fractionation of fasting (6 hr) plasma TGs 
revealed a significant increase in the plasma VLDL fraction of HFHC-fed mice, which 
was significantly attenuated with nobiletin treatment (Figure 2-22-B). Interestingly, 2 
hours following the olive oil gavage, the TG AUC of the VLDL/chylomicron fraction of 
HFHC did not significantly increase from baseline, suggesting delayed intestinal-TG 
excursion (Figure 2-22D). By contrast, the TG AUC of the VLDL/chylomicron fraction 
of nobiletin-treated mice significantly increased from baseline (Figure 2-22D), suggesting 
increased intestinal-TG excursion.  
 
In mice following an olive oil gavage, the secretion of TG into plasma from the intestine 
is primarily in chylomicrons and VLDL-sized particles. In another set of mice, we 
isolated the plasma chylomicron fraction and the VLDL fraction separately by 
ultracentrifugation. In the chylomicron fraction, triglyceride concentration peaked at 2 
hours following the olive oil gavage in HFHC-fed mice (Figure 2-23A). The 
chylomicron-triglyceride peak in nobiletin treated mice, however, occurred at the 1-hour 
time-point (Figure 2-23A). In the VLDL fraction, which is largely intestinally derived, 
triglycerides peaked once again 2-hours following the oral fat load in HFHC-fed mice, 
whereas this peak appeared at the 1-hour time point in nobiletin treated mice (Figure 
23B). The shift in triglyceride peak in both chylomicrons and VLDL from 2-hours to 1-
hour post-gavage and reduced triglyceride AUC with nobiletin treatment suggests 
enhanced secretion of intestinally derived triglyceride occurs within the first hour and is 









Figure 2-22 Postprandial plasma triglyceride response. 
 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A) 
Plasma triglyceride concentration at baseline (6 hour fast) and at 2, 4, 6 and 8 hours after 
an olive oil gavage. In another set of mice, plasma was collected following a 6 hour fast 
and at 2 hours after mice were challenged with an oral gavage of olive oil. Plasma was 
subjected to fast protein liquid chromatography (FLPC) and triglycerides were measured 
in each fraction by enzymatic assay (n=8-12/group). (B) Fasting plasma triglycerides. (C) 
Plasma triglycerides 2 hours post olive oil gavage. (D) Fasting and post gavage plasma 
VLDL triglyceride AUC calculations and absolute change from baseline (Δ). Values are 
the mean ± SEM. * indicates statistical significance between HFHC-fed mice and HFHC 
+ nobiletin-fed mice by repeated measures Two-Way Anova with post-hoc Tukey test, 
P<0.05. Statistical difference between groups at fasting are indicated by different 
uppercase letters, differences between groups 15 min post-gavage are indicated by 
different lowercase letters and differences between the delta (15min-0hr) from baseline in 
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Figure 2-23 Postprandial plasma triglyceride response. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A) 
Plasma triglyceride concentration at baseline (6 hour fast) and at 2, 4, 6 and 8 hours after 
an olive oil gavage. In another set of mice, plasma was subjected to ultracentrifugation to 
isolate the (A) Chylomicron fraction and the (B) VLDL fraction triglyceride 
concentration at baseline (6 hour fast) and at 1, 2 and 4 hours after an olive oil gavage. * 
indicates statistical significance between HFHC-fed mice and HFHC + nobiletin-fed mice 
by repeated measures Two-Way Anova with post-hoc Tukey test, P<0.05.   
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2.3.6.3 Nobiletin increases intestinal-TG secretion following an 
oral-fat gavage 
To directly determine intestinal-TG secretion rates, plasma was collected from 6-hour 
fasted mice following an injection of poloxamer-407, an inhibitor of lipoprotein 
catabolism, and challenged with an oral gavage of 3H-triolein in olive oil (Figure 2-24A). 
Plasma triglycerides were plotted as a change from baseline (6-hr fast). HFHC-fed mice 
displayed a delayed appearance of TG mass in the plasma, which was significantly 
corrected with nobiletin treatment (Figure 2-24B). The appearance of 3H-TG into to 
plasma was also significantly delayed, particularly 2 hours post-gavage in HFHC-fed 
mice, whereas the rate of appearance of 3H-TG in plasma was also significantly 
increased with nobiletin treatment (Figure 2-24B). Despite the delayed dietary TG 
secretion in the HFHC-fed mice, there was no significant change in plasma apoB48 
secretion between HFHC + nobiletin and HFHC alone(Figure 2-25). Although mice 
produce apoB48 as a scaffold for both intestinal and liver lipoprotein formation, the 
plasma apoB48 signal measured post-olive oil gavage was likely dominated by the 
intestinal contribution.  
 
To determine if nobiletin alters TG secretion from the intestine compared mice fed the 
HFHC-diet alone, we measured plasma, chylomicron fraction and VLDL fraction TG 
before and at 2 hours following an olive oil gavage in mice treated with poloxamer-407. 
As previously shown by others [23, 25], HFHC-fed mice displayed a significantly lower 
TG secretion into plasma 2 hours after the olive oil gavage (Figure 2-26A). Nobiletin 
significantly increased plasma TG secretion at this time point (Figure 2-26A). HFHC-fed 
mice also displayed a delayed TG secretion in the chylomicron fraction and in the VLDL 
fraction of plasma (Figure 2-26 B&C). Nobiletin significantly increased TG secretion in 
both fractions (Figure 2-26 B&C). We did not detect a difference in apoB48 secretion at 
2 hours in the chylomicron fraction between diet groups (Figure 2-26D), indicating that 
nobiletin loaded more TG onto each apoB48 particle in the chylomicron fraction 
compared to HFHC alone. However, a significantly decreased apoB48 secretion at 2 
hours was observed in the VLDL fraction in HFHC-fed mice, which was attenuated by 
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nobiletin (Figure 2-26 E). This suggests that nobiletin increased the number of apoB48 
particles into the VLDL fraction.  
When comparing the ratio of apB48 to TG mass within each fraction, as a surrogate for 
measuring particle size, a trend for increase was observed in the HFHC-fed mice in the 
chylomicron fraction, suggesting a decrease in TG content per lipoprotein particle at 2 
hours (Figure 2-27A). This trend for decrease was reversed with nobiletin treatment 
(Figure 2-27A). In the VLDL fraction, the opposite trend was observed: HFHC-fed mice 
appeared to increase their TG content per lipoprotein particle (likely intestinally derived) 
at 2 hours (Figure 2-27B). Together, this suggests that nobiletin enhances intestinal TG 
secretion by increasing TG content in the chylomicron fraction as well as increasing the 










Figure 2-24 Postprandial plasma triglyceride response. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted (6 hours) and administered poloxamer-407 (i.p.), and 30 minutes later 
received an oral gavage of 200 µL of olive oil containing [3H]triolein. Half of the mice 
were sacrificed at 2 hours and the other half at 4 hours post-gavage. Plasma was collected 
from mice following a 6 hour fast and 1, 2, and 4 hours post-gavage for (A) Plasma 
triglyceride mass and  (B) Plasma [3H]triglyceride expressed as a difference from 
baseline and the area under the curve (AUC) calculations. Values are the mean ± SEM, 
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Figure 2-25 Postprandial plasma triglyceride response. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted (6 hours) and administered poloxamer-407 (i.p.), and 30 minutes later 
received oral gavage of 200 µL of olive oil containing [3H]triolein. Half of the mice were 
sacrificed at 2 hours and the other half at 4 hours post-gavage. Plasma was collected from 
mice following a 6 hour fast and 1, 2, and 4 hours post-gavage for (A) Plasma apoB48 
signal determined by immunoblot and expressed as a difference from baseline and area 
under the curve (AUC) calculations. A representative immunoblot of apoB48 is shown 
below. Values are the mean ± SEM, different letters are statistically different, by 
ANOVA with post-hoc Tukey test, P<0.05.  
 
  






















































Figure 2-26 Nobiletin enhances intestinally derived triglyceride secretion following 
an oral fat load. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A) 
Plasma triglyceride concentration at baseline (6 hour fast) and at 2 hours after an olive oil 
gavage. Plasma was ultracentrifuged to isolate the (B) chylomicron fraction and the (C) 
VLDL fraction triglyceride concentration at baseline (6 hour fast) and at 2 hours after the 
olive oil gavage. ApoB48 levels were measured by immunoblot and normalized to 
albumin in the (D) chylomicron and (E) VLDL fraction. A representative immunoblot of 
apoB48 is shown below. Values are the mean ± SEM. Statistical difference between 
groups at fasting are indicated by different uppercase letters, differences between groups 
2 hours post-gavage are indicated by different lowercase letters and differences between 
the delta (2hr-0hr) from baseline in each group are indicated by different symbols by 
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Figure 2-27 Estimate of lipoprotein particle size. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. 
ApoB48:TG ratio was calculated as a surrogate measure of particle size within the (A) 
Chylomicron fraction and (B) VLDL fraction. Values are the mean ± SEM, different 
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2.3.6.4 Nobiletin increases intestinal-TG clearance following an 
oral-fat gavage 
To establish an estimate chylomicron TG clearance rate, we compared chylomicron 
fraction TG secretion rates (with poloxamer-407 treatment) to chylomicron TG changes 
from baseline (without poloxamer-407 treatment) in the same set of mice 2 hours after an 
olive oil gavage (Figure 2-28A). When subtracting the absolute values, we were able to 
derive an estimate of the clearance rate. The HFHC-diet suppression of chylomicron TG 
clearance was significantly reversed by nobiletin treatment (Figure 2-28B). Therefore, in 
addition to increasing intestinal chylomicron TG secretion, nobiletin decreases 









Figure 2-28 Estimate of intestinally-derived triglyceride clearance rate. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A) 
Comparison of chylomicron-fraction secretion rates in mice treated with poloxamer-407 
(circles) and in mice without poloxamer-407 (triangles) 2 hours after an acute dietary 
challenge. (B) Estimated clearance rate. Values are the mean ± SEM, different letters are 
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2.3.6.5 Nobiletin influences the expression of genes involved in 
intestinal lipid metabolism 
CD36, DGAT2 and MTP are involved in fatty acid trafficking, TG synthesis and TG 
loading onto apoB48 for chylomicron assembly, respectively [26]. Since nobiletin 
significantly reduced jejunal TG mass 2-hours post-oil gavage compared to HFHC-fed 
mice and that changes in jejunal gene expression have been reported to occur at 2-hours 
post-oil gavage in lean versus obese mice [25], jejunal mucosa scrapings were analyzed 
for mRNA expression by qRT-PCR at this time point. There was a trend to increased 
Cd36 expression in HFHC-fed mice, but not with nobiletin treatment (Figure 2-29A). 
There was no change in the expression of Dgat2 between diets (Figure 2-29B). 
Additionally, there was no change in Mttp expression (Figure 2-29C). As in the fasted 
state, Srebf1c expression in HFHC-fed mice was significantly increased 2 hours post-
olive oil gavage, which was completely corrected by nobiletin (Figure 2-29D). Adipose 
triglyceride lipase (ATGL) mediates the hydrolysis of triglyceride from CLDs, and its 
expression has previously been shown to be reduced from baseline 2-hours following an 
olive oil gavage in high-fat fed mice [27]. The addition of nobiletin to the HFHC diet 
significantly increased Atgl mRNA abundance compared to that of HFHC-fed mice, 
which may increase substrate for chylomicron synthesis rather than storage (Figure 2-
29E). Plin2 is involved in CLD stabilization and hydrolysis; there was a non-significant 
trend for increase in its expression with nobiletin compared to HFHC-fed mice.  
 
Collectively, these results indicate that addition of nobiletin to the HFHC diet prevents 
intestinal triglyceride accumulation, in part, by preventing HFHC-diet induced increase in 
postprandial Srebf1c expression, thereby limiting non-dietary TG substrate for intestinal 
120 
 
lipoprotein formation. Furthermore, the increased expression of Atgl and Plin2 suggest 
enhanced liberation of fatty acids stored in CLDs for either oxidation or TG re-synthesis 
for chylomicron formation. As such, the jejuna of nobiletin-treated mice are more 









Figure 2-29 Nobiletin influences the expression of genes involved in intestinal 
triglyceride metabolism. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks.  
Expression of (A) Cd36, (B) Dgat2, (C) Mttp, (D) Srebf1c, (E) Atgl and (F) Plin2 in 
jejunal mucosa scrapings by qRT-PCR. Values are the mean ± SEM, different letters are 
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2.3.7 Evidence for a possible mechanism involving gut hormones 
2.3.7.1 Nobiletin improves physical gut parameters 
It has been previously shown that chronic high-fat feeding in mice shortens the length of 
the small intestine and modulates metabolic endotoxemia [28]. The HFHC diet 
significantly shortened small intestinal length, which was corrected by nobiletin (Figure 
2-30A). A representative image is shown in Figure 2-30C. Similarly, the HFHC-diet 
suppression of small intestinal wet weight was increased by nobiletin (Figure 2-30B). 
Nobiletin also increased fasting (6 hr) crypt-villus height compared to HFHC and chow-
fed mice (Figure 2-30D; Representative images Figure 2-30F). To determine if nobiletin's 
influence on small intestinal length and weight impacted gut-barrier function, we 
measured plasma lipopolysaccharide (LPS) in HFHC- and HFHC + nobiletin-fed mice 
following a 6 hour fast. Nobiletin significantly reduced fasting plasma LPS (Figure 2-
30E) suggesting improved barrier function. At this stage, it remains unknown whether the 
effect of nobiletin on small intestinal length, weight and barrier function are linked to the 
prevention of intestinal lipid accumulation or systemic metabolic protection by nobiletin. 
Interestingly, gut hormone glucagon-like peptide 2 (GLP-2) has been shown to improve 
all of these parameters and increase intestinal TG secretion.  
 
2.3.7.2 Nobiletin increases plasma GLP-1 in response to an oral 
fat challenge 
As previously mentioned, GLP-1 lowers glycemia and post-prandial plasma chylomicron 
triglycerides in response to a meal [7]. In the present study, a significant increase in 
fasting plasma GLP-1 concentrations were observed in nobiletin treated mice (Figure 2-
31). In response to an acute dietary fat challenge, plasma GLP-1 levels were increased 
after 10 minutes in all three diet groups, where absolute plasma GLP-1 levels at 10 
minutes were significantly increased with nobiletin treatment, compared to HFHC alone 
and chow-fed mice (Figure 2-31). Reliable assays for plasma GLP-2 in mice are not 
currently available [7]. However, as GLP-1 and GLP-2 are products of the same gene, it 









Figure 2-30 Nobiletin improves physical gut parameters. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. Mice 
were fasted for 6 hours and whole intestines were removed for (A) Small intestinal length 
(B) small intestinal weight measurements as well as (C) representative photomicrographs 
of small intestinal sections. Fasting crypt-villus height was measured in frozen sections (8 
µm) of jejunal segments, prepared using a cryostat, stained with Oil Red O and 
counterstained with hematoxylin. (F) Representative photomicrographs. (D) Fasting (6 
hour) plasma lipopolysaccharide in HFHC and HFHC+nobiletin fed mice determined by 
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 increased GLP-2. As the plasma half-life of GLP-2 is 7-fold longer than that of GLP-1, it 
is assumed that the metabolic effects of endogenous GLP-2 predominate over those of 
endogenous GLP-1 [7]. Nevertheless, these data suggest that nobiletin may increase 










Figure 2-31 Nobiletin increases plasma GLP-1. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks. (A) 
GLP-1 was measured at fasting (6 hour) and 10 minutes after an oral fat load determined 
by Mesoscale. Statistical difference between groups at fasting are indicated by different 
uppercase letters, differences between groups 10 min post-gavage are indicated by 
different lowercase letters and differences between the delta (10min-0hr) from baseline in 
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2.3.8 Treatment with GLP-2 receptor antagonist GLP-2 (3-33) 
GLP-2 is known to increase intestinal fat absorption and chylomicron-triglyceride 
secretion into plasma [9]. To determine if nobiletin increases intestinal triglyceride 
secretion by increasing endogenous levels of gut-derived GLP-2, we treated chow, HFHC 
and HFHC + nobiletin fed mice with 30 ng/day of the GLP-2 receptor antagonist GLP-2 
(3-33) or PBS subcutaneously at 11am daily for 14 days following a 10-week feeding 
period. Body weight did not significantly change between treatment groups during the 14 
injection days (Figure 2-32B).  
2.3.8.1 Effect of GLP-2 receptor antagonist, GLP-2 (3-33), 
treatment on hepatic lipids 
In similar experiments, another group found worsened hepatic steatosis following 
treatment of high fat-fed mice with 30 ng and 60 ng GLP-2 (3-33) [29]. In the present 
study, two hours after the dietary fat challenge, we found that GLP-2 (3-33) treatment did 
not significantly increase hepatic triglyceride (Figure 2-33A) in HFHC-fed mice, 
however, a significant increase was observed in GLP-2 (3-33)-treated HFHC + nobiletin-
fed mice compared to PBS control. GLP-2 (3-33) did not significantly increase hepatic 
free cholesterol (Figure 33B) and hepatic cholesterol ester mass (Figure 2-33C) in either 
HFHC or HFHC + nobiletin mice compared to vehicle controls. 
2.3.8.2 Effect of GLP-2 receptor antagonist, GLP-2 (3-33), 
treatment on physical gut parameters 
GLP-2 is an intestinotrophic gut hormone and a treatment for short bowel syndrome [7]. 
Two hours after the dietary fat challenge, GLP-2 (3-33) treatment had no significant 
effect on intestinal length (Figure 2-34A) in all three diet groups compared to vehicle 
controls. Small intestinal weight and cecal weight were unchanged among all three diet 










Figure 2-32 Treatment with a GLP-2 receptor antagonist, GLP-2 (3-33). 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks 
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (3-
33) or PBS (control) by subcutaneous injection (n=8/treatment groups/diet). (A) Time 
course of body weight during the 10-week feeding period. (B) Time course of body 
weight during the 14 day injection period. Values are the mean ± SEM, * indicate 
statistical difference between HFHC-fed and HFHC + nobiletin-fed mice by repeated 
measures Two-Way Anova with post-hoc Tukey test, P<0.05. N.S. indicates no 
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Figure 2-33 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on 
hepatic lipids. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks 
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (3-
33) or PBS as a control by subcutaneous injections (n=8/treatment groups/diet). (A) 
Hepatic triglycerides (B) Hepatic free cholesterol and (C) Hepatic cholesterol ester mass 
2 hours after an olive oil gavage. Values are the mean ± SEM. Statistical difference 
between control groups are indicated by different uppercase letters, differences between 
treatment groups are indicated by different lowercase letters by ANOVA with post-hoc 
Tukey test, P<0.05. Differences between control and treatment groups within a diet 
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Figure 2-34 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on 
physical gut parameters. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks 
(n=16/group).  Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (3-
33) or PBS as a control by subcutaneous injections (n=8/treatment groups/diet). (A) 
Small intestinal length, (B) Small intestinal weight and (C) Cecal weight 2 hours after an 
olive oil gavage. Values are the mean ± SEM. Statistical difference between control 
groups are indicated by different uppercase letters, differences between treatment groups 
are indicated by different lowercase letters by ANOVA with post-hoc Tukey test, 
P<0.05. Differences between control and treatment groups within a diet group are 
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2.3.8.4 Effect of GLP-2 receptor antagonist, GLP-2 (3-33), 
treatment on jejunal lipids following an olive-oil gavage 
 
Pharmacological doses of GLP-2 have been shown to increase intestinal triglyceride 
secretion [9]. To determine if nobiletin requires intact GLP-2 signaling to increase-TG 
secretion from the intestine, we measured jejunal lipids two hours after an olive oil 
gavage, as outlined in our experimental design (Figure 2-35A). GLP-2 (3-33) treatment 
did not significantly change jejunal TG mass in chow, HFHC-fed or nobiletin treated 
mice compared to vehicle controls (Figure 2-35B). Jejunal free cholesterol mass was not 
significantly increased with GLP-2 (3-33) compared to vehicle controls (Figure 2-35C). 
2.3.8.5 Effect of GLP-2 receptor antagonist, GLP-2 (3-33), 
treatment on intestinal-TG secretion 
The triglyceride content of plasma chylomicron and VLDL fractions were measured 
before and at 2 hours following an olive oil gavage and poloxamer-407 administration in 
mice treated with GLP-2 (3-33) for 14 days. GLP-2 (3-33) treatment did not significantly 
alter triglyceride secretion in the chylomicron or VLDL fractions in chow HFHC-fed or 
nobiletin-treated mice compared to vehicle controls (Figure 2-36A&B). GLP-2 (3-33) 
treatment did not significantly alter apoB48 secretion at 2 hours in the chylomicron 
fraction between diet groups (Figure 2-37). 
Collectively, these results suggest that the GLP-2 (3-33) treatment did not significantly 
impact postprandial hepatic, intestinal and plasma lipid metabolism. Moreover, the 
assumed increase in endogenous levels of GLP-2 with nobiletin treatment appeared to not 









Figure 2-35 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on 
jejunal triglycerides 2 hours after an olive oil gavage. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks 
(n=16/group).  Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (3-
33) or PBS as a control by subcutaneous injections. Mice were fasted (6 hours) at the 
beginning of the light cycle and injected with poloxamer-407 (i.p.) and 30 min later 
received an olive oil via oral gavage (A). Jejuna were removed and cleaned for lipid 
determinations. (B) Jejunal triglyceride mass and (C) Jejunal free cholesterol mass. 
Values are the mean ± SEM. Statistical difference between control groups are indicated 
by different uppercase letters, differences between treatment groups are indicated by 
different lowercase letters by ANOVA with post-hoc Tukey test, P<0.05. Differences 
between control and treatment groups within a diet group are indicated by * by Student's 
unpaired t-test P<0.05. 
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Figure 2-36 Effect of treatment with GLP-2 receptor antagonist, GLP-2 (3-33), on 
intestinal TG secretion 2 hours after an olive oil gavage. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks 
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (3-
33) or PBS as a control by subcutaneous injections. Plasma was ultracentrifuged to 
isolate the (A) chylomicron fraction and the (B) VLDL fraction. Triglyceride 
concentrations were determined at baseline (6 hour fast) and at 2 hours after the olive oil 
gavage. Values are the mean ± SEM. Statistical differences between control groups are 
indicated by different uppercase letters at fasting (A-B) and 2 hours post-gavage (C-D) 
by ANOVA with post-hoc Tukey test, P<0.05. Statistical differences between treatment 
groups are indicated by different lowercase letters at fasting (a-c) and 2 hours post-
gavage (d-e) by ANOVA with post-hoc Tukey test, P<0.05. Different symbols indicate 
statistical difference between the delta from baseline (2hr-0hr) in control groups (# or &) 
and treatment groups (% or @) by ANOVA with post-hoc Tukey test, P<0.05. 
Differences between control and treatment groups within a diet group are indicated by * 
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Figure 2-37 Effect of treatment with a GLP-2 receptor antagonist, GLP-2 (3-33), on 
intestinal apoB48 secretion 2 hours after an olive oil gavage. 
Male Ldlr-/- mice were fed a chow, HFHC, or HFHC + nobiletin diet for 10 weeks 
(n=16/group). Mice were then treated at 11am daily for 14 days with 30 ng of GLP-2 (3-
33) or PBS (control) by subcutaneous injections. Plasma was ultracentrifuged to isolate 
the chylomicron fraction. (A) Apob48 levels were measured by immunoblot and 
normalized to albumin in the chylomicron fraction at baseline (6 hour fast) and at 2 hours 
after the olive oil gavage. Representative immunoblot is shown below. Values are the 
mean ± SEM. Statistical differences between control groups are indicated by different 
uppercase letters at fasting (A-B) and 2 hours post-gavage (C-D) by ANOVA with post-
hoc Tukey test, P<0.05. Statistical differences between treatment groups are indicated by 
different lowercase letters at fasting (a-c) and 2 hours post-gavage (d-e) by ANOVA with 
post-hoc Tukey test, P<0.05. Different symbols indicate statistical difference between the 
delta from baseline (2hr-0hr) in control groups (# or &) and treatment groups (% or @) 
by ANOVA with post-hoc Tukey test, P<0.05. Differences between control and 
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2.3.9 Investigating the ability of nobiletin to correct metabolic 
dysregulation and intestinal lipid metabolism in female Ldlr-/- 
mice fed a HFHC diet 
 
All nobiletin studies to date have been performed in male mice. To determine if 
observations previously documented systemically as well as the intestine the intestine 
extend to female mice, we examined the major outcomes of nobiletin treatment in one 
study of female mice (n=59).   
2.3.9.1 Nobiletin prevents HFHC-diet induced obesity in female 
Ldlr-/- mice 
Female Ldlr-/- mice were fed a chow, a HFHC diet, or a HFHC diet supplemented with 
0.3% nobiletin (w/w) for 12 weeks. Weight rapidly increased in mice fed the HFHC diet, 
which was prevented by supplementation of nobiletin to the same diet (Figure 2-38A). 
The prevention of HFHC-induced weight gain was independent of caloric intake (Figure 
38B). Moreover, gonadal and inguinal fat pad weights were significantly increased in 
HFHC-fed mice and this increased adiposity was prevented with nobiletin treatment 
(Figure 2-38C&D). Liver weight was also increased with HFHC-feeding, which was 
prevented by nobiletin treatment (Figure 2-38E). Therefore as in male mice, nobiletin 
prevents HFHC-diet induced weight gain and obesity. 
 
2.3.9.2 Hepatic and plasma lipid metabolism in female Ldlr-/- mice 
In female Ldlr-/- mice fed the HFHC diet, the presence of increased dietary fat and 
cholesterol promoted the development of hepatic steatosis, as these mice displayed 
elevated triglyceride, free cholesterol and cholesteryl ester mass in their livers (Fig 2-
39A-C). Nobiletin-treatment significantly prevented hepatic triglyceride (Figure 2-39A) 
but surprisingly, not cholesterol accumulation (Figure 2-39B&C). These effects on 
hepatic lipids were reflected in plasma. HFHC-fed mice displayed a significant increase 
in fasting plasma TG, which was corrected by nobiletin (Figure 2-40A). FPLC 
fractionation revealed a 3-fold increase in the TG content of VLDL particles in HFHC-
fed mice (Figure 2-40B). Nobiletin treatment reduced the fasting VLDL-TG AUC by 
144 
 
~50% (Figure 40B). As expected, HFHC-fed mice displayed a significant increase in 
fasting plasma cholesterol (Figure 2-41A). The addition of nobiletin to the HFHC, 
however, did not attenuate fasting plasma cholesterol levels (Figure 2-41B). FPLC 
fractionation revealed a 5-fold increase in VLDL cholesterol and a 3-fold increase in 
LDL cholesterol in HFHC-fed mice, whereas the addition of nobiletin had no effect on 
these parameters (Figure 2-41B). Therefore, as in male mice, nobiletin prevents HFHC 
diet-induced increases in fasting VLDL-TG in female Ldlr-/- mice. Unlike in male mice, 
nobiletin does not prevent HFHC diet-induced perturbations in VLDL and LDL 











Figure 2-38 Nobiletin prevents HFHC diet-induced weight gain and obesity in 
female Ldlr-/- mice. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. (A) Body weight gain. (B) Caloric intake expressed as kcal/g body 
weight/day. (C) Gonadal and (D) inguinal fat pad weights. (E) Liver weights of mice 
sacrificed in the fasted state (n=7-8/group). Values are the mean ± SEM. * indicate 
differences in body weight in HFHC-fed mice compared to HFHC + nobiletin-fed mice 
by repeated measures Two-Way Anova with post-hoc Tukey test, P<0.05. Different 
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Figure 2-39 Nobiletin attenuates hepatic lipid accumulation in HFHC-fed female 
Ldlr-/- mice. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. Mice were sacrificed after a 6 hour fast. Hepatic (A) triglyceride (TG) 
(B) free cholesterol (FC) and (C) cholesteryl ester (CE) mass determined following lipid 
extraction. Values are the mean ± SEM, different letters are statistically different, by 
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Figure 2-40 Plasma triglyceride analyses in nobiletin treated female Ldlr-/- mice. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. Mice were sacrificed after a 6 hour fast. (A) Fasting plasma total 
triglyceride (TG). Plasma was subjected to fast protein liquid chromatography (FPLC) 
and TG concentrations were measured in eluted fractions (n=7-8/group). (B) Fasting 
plasma triglyceride (TG). (C) Plasma FPLC VLDL triglyceride (TG) area under the curve 
(AUC) (fractions 5-10). Values are the mean ± SEM, different letters are statistically 
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Figure 2-41 Plasma cholesterol analyses in nobiletin treated female Ldlr-/- mice. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. (A) Fasting plasma total cholesterol. Plasma was subjected to fast 
protein liquid chromatography (FPLC) and cholesterol concentrations were measured in 
eluted fractions (n=7-8/group). (B) Fasting plasma cholesterol. (C) Plasma FPLC VLDL 
cholesterol area under the curve (AUC) (fractions 5-10). (D) Plasma FPLC LDL 
cholesterol AUC (fractions 11-19). Values are the mean ± SEM, different letters are 
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2.3.9.3 Nobiletin attenuates HFHC-diet induced jejunal lipid 
accumulation in female Ldlr-/- mice 
Lipid mass was quantified in jejunal mucosal scrapings of 6 hour-fasted mice. The HFHC 
diet-induced increase in jejunal triglyceride mass was markedly attenuated by the 
addition of nobiletin to the same diet (Figure 2-42A). Cholesteryl ester mass was also 
increased in the jejunum of HFHC fed mice, however, a similar increase was detected 
with nobiletin treatment (Figure 2-42B). Therefore, as in male mice, nobiletin prevents 
HFHC diet-induced increases in fasting jejunal TG accumulation in female Ldlr-/- mice. 
Unlike in male mice, nobiletin does not prevent HFHC-diet induced jejunal CE 
accumulation. 
2.3.9.4 Postprandial jejunal lipid metabolism in female Ldlr-/- mice 
To determine if nobiletin prevents intestinal triglyceride accumulation in the postprandial 
state in female mice, we quantified lipid mass in jejunal mucosa scrapings, 2-hours after 
an olive oil gavage (Figure 2-43A). Triglyceride mass in the mucosa of the jejunum did 
not differ between diet groups, rather a trend for increase in mass was observed in the 
nobiletin treated mice (Figure 2-43A). Total cholesterol mass did not differ between diet 
groups (Figure 2-43B). Therefore unlike in male mice, nobiletin does not prevent HFHC 
















Figure 2-42 Nobiletin attenuates fasting jejunal lipid accumulation in HFHC-fed 
female Ldlr-/- mice. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. Mice were sacrificed after a 6 hour fast and jejunum was removed for 
lipid analysis (n=7-8/group). Fasting (A) triglyceride (TG) and (B) cholesteryl ester (CE) 
mass in jejunal mucosa scrapings. Values are the mean ± SEM, different letters are 
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Figure 2-43 Postprandial jejunal lipid accumulation in HFHC-fed female Ldlr-/- 
mice. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. Mice were fasted (6 hours), injected with poloxamer-407 (i.p.) and 30 
min later received an olive oil gavage (A). Jejuna were removed and cleaned for lipid 
determinations (n=8-12/group). Jejunal mucosa (B) triglyceride (TG) and (C) total 
cholesterol (TC) mass. Values are the mean ± SEM, different letters are statistically 
different, by ANOVA with post-hoc Tukey test, P<0.05. N.S. indicates no statistical 
significance.  
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2.3.9.5 Nobiletin enhances intestinally derived TG secretion 
following an oral fat load in female Ldlr-/- mice 
To determine if nobiletin prevents the HFHC diet-induced delay in intestinal TG 
secretion in female mice as it does in male mice, we measured plasma, chylomicron 
fraction and VLDL fraction triglycerides before and 2 hours following an olive oil 
gavage in mice treated with poloxamer-407. HFHC-fed mice displayed significantly 
lower plasma triglyceride secretion 2 hours after the olive oil gavage and no difference 
was observed with nobiletin treatment (Figure 2-44A). HFHC-fed mice also displayed 
delayed secretion of both chylomicron TG and VLDL TG (Figure 2-44B&C). Nobiletin 
significantly increased TG secretion in both fractions compared to HFHC alone (Figure 
2-44B&C). ApoB48 secretion at 2 hours in the chylomicron fraction was not different 
among the 3 diet groups. However, absolute values at fasting and 2-hours post gavage 
were similar in HFHC and HFHC + nobiletin-fed mice (Figure 2-44D) suggesting that 
nobiletin increased the amount of TG per chylomicron particle secreted. Therefore 
nobiletin increases intestinal TG secretion in both male and female Ldlr-/- mice compared 
to mice fed the HFHC diet alone. 
2.3.9.6 Expression of genes involved in intestinal lipid metabolism 
in female Ldlr-/- mice 
While it appeared that nobiletin increased intestinal triglyceride secretion 2 hours after an 
acute dietary fat challenge, nobiletin did not prevent HFHC-diet-induced increases in 
jejunal lipid accumulation following the olive oil gavage. Therefore, the remaining 
triglyceride mass may be derived from de novo synthesis. Srebf1c expression in HFHC-
fed mice was significantly increased 2 hours post-olive oil gavage, which was not 
corrected with nobiletin treatment (Figure 2-45A). There was a non-significant trend for 
increase in Plin2 expression with nobiletin treatment compared to HFHC-fed mice. 
Therefore, unlike in male mice, nobiletin did not prevent HFHC-diet induced increase in 
Srebpf1c expression in female Ldlr-/- mice. Nobiletin treatment appears to induce a trend 










Figure 2-44 Nobiletin enhances intestinal TG secretion following an oral fat load in 
female Ldlr-/- 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. Mice were fasted (6 hours) injected with poloxamer-407 (i.p.) and 30 
min later received an olive oil gavage (n=8-12/group). (A) Plasma triglyceride (TG) 
concentration at baseline (6 hour fast) and at 2 hours after an olive oil gavage. Plasma 
was ultracentrifuged to isolate the (B) chylomicron fraction and the (C) VLDL fraction 
and TG concentrations are shown at baseline (6 hour fast) and at 2 hours after the olive 
oil gavage. ApoB48 levels were measured by immunoblot and normalized to albumin in 
the (D) chylomicron fraction. Values are the mean ± SEM. Statistical difference between 
groups at fasting are indicated by different uppercase letters, differences between groups 
2 hours post-gavage are indicated by different lowercase letters and differences between 
the delta (2hr-0hr) from baseline in each group are indicated by different symbols by 















































Chow HFHC HFHC + 
Nob 









































Chow HFHC HFHC + 
Nob 


















Chow HFHC HFHC + Nob 
∆ 0h 2h ∆ 0h 2h ∆ 0h 2h 
Chow HFHC HFHC + 
Nob 











Figure 2-45 Expression of genes involved in intestinal lipid metabolism. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. Mice were fasted (6 hours), injected with poloxamer-407 (i.p.) and 30 
min later received an olive oil gavage (n=8-12/group). Expression of (A) Srebf1c and (B) 
Plin2 in jejunal mucosa scrapings by qRT-PCR. Values are the mean ± SEM, different 
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2.3.9.7 Nobiletin prevents HFHC-diet-induced physical changes to 
gut parameters in female Ldlr-/- mice. 
The HFHC-diet significantly reduced small intestinal length (Figure 2-46A) and weight 
in female mice (Figure 2-46B). Nobiletin significantly attenuated HFHC-diet induced 
shortening of the small intestine and increased intestinal weight to values observed in 
chow-fed mice (Figure 2-46A&B). The HFHC-diet significantly reduced cecal mass, 
independent of nobiletin treatment (Figure 2-46C). The prevention of HFHC diet-induced 
shortening of the small intestine by nobiletin in female Ldlr-/- mice, as shown in male 













Figure 2-46 Nobiletin prevents HFHC-diet induced physical changes to gut 
parameters in HFHC-fed female Ldlr-/- mice. 
Female Ldlr-/- mice, (n=16-22/group) were fed a chow, a HFHC or a HFHC + nobiletin 
diet for 12 weeks. (A) Small intestinal length, (B) small intestinal weight and (C) cecal 
weight 2 hours post-olive oil gavage. Values are the mean ± SEM, different letters are 
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There is intense debate whether alteration in intestinal lipid metabolism is the result of a 
normal adaptation to ensure absorption of chronic high-fat feeding or the result of 
obesity-induced dysregulation in mice [9]. In this thesis, we showed that 10 weeks of 
HFHC-feeding caused aberrant intestinal insulin signaling and increased intestinal de 
novo lipogenesis, which provided increased substrate for chylomicron synthesis, CLD 
formation and therefore prolonged postprandial lipemia. Furthermore, the increased free 
fatty acid concentrations in the insulin resistant HFHC-fed mice were linked to increased 
intestinal triglyceride synthesis providing even more TG substrate. The addition of 
nobiletin to the HFHC diet improved intestinal insulin sensitivity and prevented intestinal 
lipid accumulation from de novo pathways, thereby allowing for efficient dietary 
triglyceride excursion from the intestine into plasma. In addition to enhanced intestinal 
TG excursion, we observed a shortened period of postprandial lipemia with nobiletin 
treatment compared to mice fed the HFHC diet alone, which could play a role in 
nobiletin's anti-atherogenic protection.  
All of the studies highlighted in Chapter 2 are acute dietary fat challenges following a 6 
hour fast. Therefore, we were not testing an acute molecular function of nobiletin. Rather, 
our acute dietary challenges, containing no nobiletin, were testing the influence of the 
background diet on handling of lipid by the intestine. As such, I became very interested 
in further exploring the dysregulation of nutrient signaling involved with HFHC feeding 
and the potential protection by nobiletin. We showed that HFHC feeding caused 
increased GIP stimulation and increased β-cell mass, which contributed to fasting and 
glucose-stimulated hyperinsulinemia. The addition of nobiletin to the HFHC diet 
corrected the GIP response to the ingestion of glucose and maintained normal β-cell 
mass, thereby allowing for normal insulin secretion and enhanced glucose tolerance. A 
potential mechanism involving gut hormones was evidenced by the increase in fasting 
and post-olive oil gavage of GLP-1, and presumably GLP-2, with nobiletin treatment. 
The involvement of GLP-2 in nobiletin's mechanism of action is not only in agreement 
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with the aforementioned increased intestinal TG secretion we observed with nobiletin 
treatment, but also with the prevention of HFHC-diet induced shortening of the small 
intestine in nobiletin supplemented mice. I investigated the influence of GLP-2 signaling 
on intestinal lipid metabolism using the GLP-2 receptor antagonist, GLP-2 (3-33). I 
expected that the nobiletin-treated mice would be the most vulnerable to the antagonist 
treatment resulting in inhibition of the nobiletin-induced improvements in intestinal lipid 
metabolism. To our surprise, the antagonist did not impact intestinal TG secretion rates in 
chow-fed or HFHC-fed mice. In HFHC+nobiletin-fed mice, we observed a trend for 
reduced intestinal TG excursion with GLP-2 (3-33) treatment, suggesting that GLP-2 
signaling may play a small role in nobiletin's ability to increase intestinal TG secretion. If 
anything, these studies underscore the gaps in our knowledge of the involvement of gut 
hormones in postprandial lipemia.  
Finally, I investigated the protection of nobiletin in HFHC-fed female Ldlr-/- mice.  As in 
male Ldlr-/- mice, nobiletin prevented HFHC-diet induced obesity, decreased VLDL 
triglycerides, attenuated small intestinal shortening and reduced hepatic and jejunal 
triglyceride accumulation. Conversely, nobiletin did not attenuate HFHC diet-induced 
increases in LDL cholesterol and hepatic cholesterol accumulation in female Ldlr-/- mice, 
all of which are corrected by nobiletin in male Ldlr-/- mice. This study provides evidence 
for either sex-specific responses to nobiletin treatment, narrowing of the molecular 
targets of nobiletin, and/or highlights sex-differences in metabolic dysregulation. 
Ultimately, this study highlights the importance of studying both sexes in a prevention 
model of metabolic syndrome. 
3.1 Nobiletin prevents HFHC diet-induced fasting jejunal 
lipid accumulation 
Previously, our laboratory has shown that significant levels of triglyceride (TG) mass 
remained in the liver and in the intestine of high fat-fed mice following a 6 hour fast but 
not in mice fed the same high fat diet supplemented with nobiletin [1]. The reduction in 
hepatic TG accumulation was due to increased expression of Pgc1α and Cpt1α as well as 
an increased hepatic fatty acid oxidation capacity [1]. Furthermore, correction of the 
hyperinsulinemia by nobiletin resulted in attenuation of Srebp-1c-mediated de novo fatty 
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acid synthesis. While the reduced intestinal TG accumulation was not investigated, this 
study importantly demonstrated that caloric intake, intestinal TG absorption, and lean 
body mass was not different between HFHC-fed and HFHC + nobiletin treated mice [1]. 
This information, along with the unchanged jejunal fatty acid oxidation capacity between 
nobiletin-treated mice compared to mice fed the HFHC-diet alone observed in the present 
studies, prompted us to investigate the contributions of de novo lipid synthesis and 
dietary fat handling to jejunal lipid accumulation. 
3.2 Intestinal insulin signaling  
The increased and unregulated adipocyte lipolysis associated with insulin resistance has 
been a well-documented source of and contributor to FA substrates for TG synthesis and 
VLDL production. In our fasting-refeeding experiments, where mice were re-fed their 
respective diets for 2 hours, we observed a significant increase in plasma insulin and FFA 
in HFHC-fed mice, which was normalized by nobiletin. While this experiment was a 
more physiological representation of nutrient-stimulated insulin secretion and resulting 
suppression of adipocyte lipolysis, the protective effects of nobiletin were likely due to a 
chronic prevention of peripheral insulin resistance rather than an acute effect of nobiletin 
on adipocytes with re-feeding HFHC + nobiletin. We observed no difference in jejunal 
Akt phosphorylation between diet groups. However, we showed that mTORC1 remains 
sensitive to insulin signaling in the fasted and re-fed state in HFHC-fed mice. FoxO1 
phosphorylation, however, was significantly blunted particularly in the re-fed state in 
HFHC-fed mice. These are the first studies to establish that HFHC-feeding induced a 
bifurcation in intestinal insulin signaling, a concept previously reported to occur in the 
liver. Importantly, nobiletin treatment significantly increased in FoxO1 phosphorylation 
in the re-fed state, which may contribute to the decreased postprandial lipemia observed 
in these mice compared to HFHC-fed mice. While the contribution of intestinal 
gluconeogenesis to hyperglycemia in HFHC-fed mice was not directly investigated in our 
studies, it has been previously reported in rats that intestinal gluconeogenesis 
significantly contributes to endogenous glucose production [2]. Interestingly, increased 
expression of glucose 6 phosphate, a direct target of FoxO1, is significantly upregulated 
in the small intestine of diabetic rats [3]. Therefore the ability of nobiletin to increase 
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postprandial FoxO1 phosphorylation may make an important contribution to the 
increased tolerance observed in our oral glucose tolerance tests. 
While mTORC1 phosphorylation was not significantly different between diet groups, the 
expression of its downstream effector, Srebf1-c, was significantly increased in both the 
fasted and re-fed states of HFHC-fed mice. Nobiletin treatment completely corrected 
fasting Srebf1-c expression and significantly attenuated its increased expression in the re-
fed state in male Ldlr-/- mice. The impact of this intestinal dysregulation of insulin 
signaling was confirmed ex vivo where the capacity to synthesize jejunal fatty acid and 
triglyceride was significantly elevated in HFHC-fed mice, but not nobiletin-treated mice. 
Therefore the prevention of HFHC-diet induced selective insulin resistance exerted by 
nobiletin treatment played an important role in limiting excess TG substrate for intestinal 




















Figure 3-1 Triglyceride processing in enterocytes in an insulin sensitive and insulin 
resistant state. 
Under normal conditions of dietary fat absorption, insulin stimulates mTORC1 and 
FoxO1 phosphorylation, leading to increased SREBP-1c-mediated de novo lipogenesis 
(DNL) and decreased gluconeogenesis, respectively. During insulin resistance, the 
increased insulin-stimulated DNL and enhanced circulating free fatty acids (FFA) 
provide excess substrate for TG storage in CLDs pool and chylomicron particle 
formation, contributing to the overproduction of chylomicron particles.  













































































FA-CoA FA-CoA + MG 
  
Insulin Resistant Intestine 
p 




3.3 Postprandial intestinal lipid metabolism 
Several studies highlight that during lipid absorption, CLDs are formed as temporary 
storage sites for dietary TG. Upon a secondary dietary fat stimulus, CLDs can undergo 
remodeling for lipolysis and transport to the ER for chylomicron production [4, 5]. 
Glucose ingestion has also been shown to stimulate chylomicron production in humans 
[6]. The increased fasting TG storage from de novo and dietary sources in HFHC-fed 
mice and the significantly diminished TG storage in nobiletin-treated mice led us to 
investigate postprandial intestinal-TG secretion rates in these mice. First, electron 
micrographs demonstrated a substantial increase in number and size of CLDs in a HFHC-
fed mouse compared to fasting, which were considerably diminished with nobiletin 
treatment. Our assumption that the phenotypes observed by TEM in one mouse per diet 
group would be representative across the diet groups was supported by the biochemical 
quantifications performed in all of the mice. Since the olive oil gavage contained a 
radiolabeled tracer, we were able to compare dietary TG to the total TG mass within the 
small intestine 2 hours post-gavage. We did not observe a significant difference in 
radiolabeled lipids throughout the entire small intestine between diet groups 2 hours post-
gavage, suggesting that the same amount of dietary TG is temporarily stored in the 
intestines of mice in all three diet groups. When comparing total TG mass in the small 
intestine 2-hours post-gavage, the HFHC-fed mice still had a higher AUC, particularly in 
the jejunum. This suggests that the elevated TG mass in HFHC-fed mice following a 6 
hour fast was not depleted even 2 hours following dietary fat stimulation. Furthermore, 
jejunal Srebf1-c expression was significantly elevated 2 hours post-olive oil gavage in 
HFHC-fed mice. Therefore, the significant increase in post-olive oil gavage intestinal 
lipid accumulation in HFHC-fed mice was contributed to by both fasting and postprandial 
de novo lipogenesis by means of mTORC1 hypersensitivity to insulin signaling. By 
contrast, the correction of intestinal insulin sensitivity by nobiletin normalized fasting 
intestinal TG mass and the decreased post-olive oil Srebf1-c expression, together limiting 
the post-olive oil gavage intestinal lipid accumulation.  
The poloxamer-407 studies revealed that the ability of nobiletin treatment to limit 
intestinal lipid storage was also achieved through significant increases in secretions of 
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total TG mass (from stored and dietary pools) and in radiolabeled TG (dietary only) into 
plasma compared to HFHC-fed mice. The increases in intestinal TG secretion with 
nobiletin treatment were consistent in the chylomicron and VLDL fractions of plasma. 
We assumed that the VLDL fraction was predominantly intestinally derived, by virtue of 
the rapid rise in plasma VLDL-TG following the acute oral fat challenge. Measuring 
radiolabeled VLDL-TG following an oral gavage of olive oil containing 3H-triolein or 
treating mice with orotic acid, which directly inhibits hepatic VLDL secretion [7], may 
provide increased certainty for this concept. However, previous tyloxapol studies (same 
effect as poloxamer-407) reported by our lab demonstrated that the addition of nobiletin 
to a high-fat diet decreased fasting VLDL-TG secretion to less than 1 mmol/L/h [1]; this 
represents less than 20% of the TG secretion rate into the plasma VLDL-TG fraction 
observed in the present study in HFHC + nobiletin-treated mice post-olive oil gavage. In 
high fat-fed mice, the fasting VLDL-TG secretion rate was decreased by nobiletin [1], 
whereas in the present study nobiletin increased the VLDL-TG secretion rate post-oil 
gavage, thus providing further evidence for an intestinal-specific effect of nobiletin on 
intestinal-TG secretion. 
Our non-poloxamer-407 studies, by contrast, demonstrated the potential detrimental 
effects of the increased jejunal TG accumulation in HFHC-fed mice. Increased jejunal 
TG accumulation lead to increased substrate for lipoprotein formation, which 
significantly contributed to HFHC-diet induced hypertriglyceridemia. I demonstrated 
through an estimation of poloxamer-407 to non-poloxamer-407 changes in chylomicron-
TG secretion that nobiletin significantly increased the plasma clearance and presumably 
peripheral uptake of intestinally-derived TG. While our studies did not directly measure 
LPL activity, VLDL and chylomicron particles compete for LPL-mediated hydrolysis, 
where the latter is the preferred substrate [8]. Therefore prolonged chylomicron secretion 
exhibited by HFHC-fed mice concomitantly extends the retention of hepatic and/or 
intestinal VLDL particles in the circulation. Conversely, the efficient secretion and 
clearance of chylomicrons in nobiletin-treated mice would appear more favourable. 
Reduced intestinal TG secretion following an olive oil gavage has been repeatedly shown 
in high fat diet-induced obese mice compared to lean mice as reported in this thesis and 
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by others [9] suggesting that differences in energy status may be driving alterations in 
intestinal triglyceride secretion. As such, HFHC-fed mice are in a less energy demanding 
state than the lean, nobiletin-treated mice following a 6 hour fast. This is further 
supported by the increased energy expenditure by nobiletin, observed in both prevention 
and intervention model of HFHC-diet induced obesity [10]. Measuring intestinal TG 
secretion rates at early, middle and late phases of obesity-reversal with nobiletin 
treatment may allow for the delineation of the requirement of obesity for delayed 
intestinal TG secretion. Additionally, our lab has recently shown that the addition of 
naringenin, a grapefruit-derived flavonoid, to a chow diet increased energy expenditure 
compared to pair-fed littermates fed the chow diet alone [11]. Determining the ability of 
nobiletin to increase intestinal TG secretion independent of obesity may uncover direct 
molecular targets. 
3.4 Nobiletin as a potential stimulus of gut hormone 
secretion 
The measurement of gut hormones and their inhibitor, DPP4, led us to uncover some 
interesting findings. We showed that HFHC-fed mice have increased fasting DPP4 
activity, increased fasting and post-OGTT GIP levels and unchanged fasting and post-
OGTT GLP-1 levels. Nobiletin-treated mice also had increased fasting DPP4 activity, 
despite this, fasting plasma GLP-1 was significantly elevated. Furthermore, increased 
plasma GIP levels were significantly attenuated with nobiletin treatment. DPP4 activity 
has been previously reported to be elevated in diabetic humans and mice; its inhibition is 
thus favourable in the setting of diabetes to promote insulin secretion [12, 13]. Our 
HFHC-fed mice, however, were not diabetic, as evidenced by the increased β-cell mass. 
Rather, our HFHC-fed mice, but not HFHC + nobiletin-fed mice, were hyperinsulinemic 
in the fasting and postprandial state, independent of increased DPP4 activity. In addition 
to its insulinotropic role, GIP signaling promotes TG storage in adipocytes in response to 
fat ingestion [14]. In the setting of high fat-feeding, hyper-secretion of GIP in turn 
potentiates obesity and hyperinsulinemia [14]. Interestingly, mice that lack the GIP 
receptor are protected from high fat diet-induced obesity due to enhanced energy 
utilization rather than storage of TG [14]. Therefore the prevention of GIP hyper-
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secretion with nobiletin treatment may play an important role in nobiletin's ability to 
prevent obesity and hyperinsulinemia in HFHC-fed mice. Furthermore, the prevention of 
GIP hyper-secretion with nobiletin treatment provided mechanistic insight into nobiletin 
ability to increase energy expenditure. Potential experiments to test this include treating 
HFHC + nobiletin-fed mice with GIPR agonists or inactive GIP analogues. Studies in 
humans and in rodents have shown that the half-life of GIP is slightly longer than that of 
GLP-1, suggesting that DPP4 preferentially targets GLP-1 [15]. Therefore, the increased 
GLP-1 levels, but not GIP levels, observed in nobiletin-treated mice may indicate a 
change in DPP4-substrate interaction.  
This was the first study, to our knowledge, to measure intestinal TG secretion in mice 
treated with GLP-2 (3-33). Despite increased plasma GLP-1, and presumably GLP-2, in 
the fasted and post-olive oil gavage states of nobiletin treated mice, GLP-2 receptor 
antagonist treatment did not impact intestinal TG secretion or metabolic protection. 
Previously, GLP-2 (3-33) has been shown to exacerbate hepatic lipid accumulation in 
high fat-fed mice, but not chow-fed mice. Furthermore, GLP-2 (3-33) was shown to 
decrease small intestinal weight, crypt-villus height and increase villus apoptosis in both 
lean and high-fat fed mice [16, 17]. In this study, we showed that HFHC-fed mice and 
HFHC+nobiletin-fed mice have increased hepatic TG and CE levels, thus confirming 
GLP-2 (3-33) action. Since all of the mice in our study were administered an olive-oil 
gavage, accurate crypt-villus measurements could not be made with a high level of 
certainty. This was a clear limitation in our study for confirming GLP-2 (3-33) action. An 
alternative experimental design would be to acutely treat mice with liraglutide, a GLP-1R 
agonist, and measure intestinal TG secretion following an olive-oil gavage. Liraglutide 
treatment should significantly decrease intestinal TG secretion as shown previously [18] 
and we would be able to determine if the assumed increased endogenous levels of GLP-2 
in nobiletin-treated mice can counteract this effect.  
The prevention of HFHC-diet induced shortening of the small intestine with nobiletin 
treatment suggested a possible involvement of intestinotrophic peptide, GLP-2. A recent 
study has shown that when mice are fed a low-fat diet with reduced fibre content, a 
shortening of the small intestine and shrinkage of the ceca of these mice were to the same 
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extent as observed in high-fat fed mice [19]. Therefore, the reduced fibre content of high-
fat diets, and not obesity, plays a major role in this phenotype. Specifically, the authors 
highlight that the reduced cecal short chain fatty acids limits energy substrates for 
intestinal growth [19]. Since the nobiletin-treated mice ingest the same amount of fibre as 
the HFHC-fed mice, yet prevent a shortening of the small intestine, it is possible that 
nobiletin plays a role in modulating short chain fatty acid production in the gut. 
Interestingly, diets high in fibre or short chain fatty acids have been shown to increase 
intestinal proglucagon mRNA levels [15], the precursor of both GLP-1 and GLP-2. 
Specifically, butyrate has been shown to increase plasma GLP-2 concentrations in rats 
[20]. Therefore, nobiletin may increase gut hormone secretion through a short chain fatty 
acid-dependent mechanism. First, it would be important to measure short chain fatty acid 
concentrations in nobiletin-treated mice. This could be further investigated by feeding the 
HFHC + nobiletin-diet to mice treated with antibiotics or to germ-free mice, which would 
inhibit or prevent short chain fatty acid formation, and measure circulating gut hormones. 
3.5 Investigating the ability of nobiletin to correct 
metabolic dysregulation and intestinal lipid metabolism 
in female Ldlr-/- mice fed a HFHC diet 
When comparing the major outcomes of nobiletin treatment in previously documented 
studies in male Ldlr-/- mice to the current female mice study, the protection against 
obesity and perturbed TG metabolism but not cholesterol metabolism was achieved. In 
terms of intestinal lipid metabolism, nobiletin attenuated fasting TG accumulation, which 
would suggest a decrease in de novo lipogenesis. Following an olive oil gavage, nobiletin 
treatment did increase chylomicron-TG secretion, however, a considerable amount of TG 
remained in the jejunum. Correspondingly, Srebf-1c expression was significantly 
elevated in both HFHC and HFHC + nobiletin-fed mice, suggesting that nobiletin did not 
fully correct intestinal insulin resistance in females. It was also surprising to see a 
protection from obesity, but not of perturbed plasma and hepatic cholesterol metabolism. 
However, our lab has previously reported in male mice that 0.1% nobiletin reduced 
plasma cholesterol concentrations to the same extent as 0.3% nobiletin treatment, without 
preventing obesity [1]. Therefore in male Ldlr-/- mice, mechanism for nobiletin's lipid-
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lowering effects are independent of obesity prevention. Additionally, it has been 
previously shown that high-fat (no cholesterol) feeding and high-fat (1.25% cholesterol) 
significantly increases hepatic cholesterol accumulation in C57BL/6J female compared to 
male mice [21]. This may suggest a role of estrogen in the potentiation of 
hypercholesterolemia in the absence of obesity, an effect resistant to nobiletin treatment. 
Further studies are required to test this concept. Furthermore, in view of the failure of 
nobiletin to correct abnormal cholesterol metabolism in female mice, future studies in 
female Ldlr-/- mice should investigate other parameters of nobiletin's metabolic 
protection, particularly the prevention of atherosclerosis. 
3.6 Final conclusions 
Nobiletin prevents high fat-diet induced metabolic dysregulations through actions in a 
variety of tissues in addition to its clock amplitude enhancing properties [53] (Figure 3-
2). In this thesis, the mechanisms underlying the prevention of intestinal triglyceride 
retention by nobiletin were investigated. In male Ldlr-/- mice, nobiletin 1) decreased 
fasting intestinal TG storage by correcting intestinal insulin signaling, which resulted in 
normalization of de novo lipogenesis; 2) attenuated intestinal TG accumulation and 
postprandial lipemia in response to an oral fat load by increasing chylomicron-TG 
secretion into plasma and enhancing plasma triglyceride clearance. The mechanisms 
underlying the increased chylomicron-TG secretion were investigated using a GLP-2R 
antagonist; however, antagonist administration did not inhibit nobiletin-induced 
chylomicron secretion. The mechanisms underlying the prevention of hyperinsulinemia 
by nobiletin were also investigated. In male Ldlr-/- mice, nobiletin: 1) normalized fasting 
and post-glucose gavage levels of the incretin GIP and 2) prevented pancreatic β-cell 
mass overexpansion. Finally, the metabolic protection by nobiletin was investigated, for 
the first time, in HFHC-fed female mice. In female Ldlr-/- mice, nobiletin: 1) prevented 
HFHC-diet induced weight gain; 2) decreased fasting intestinal TG storage; 3) increased 
chylomicron-TG secretion in response to an oral fat load and 4) attenuated hepatic TG 
mass. Unlike the male Ldlr-/- mice, nobiletin did not prevent perturbed cholesterol 
metabolism. Collectively, these studies provide evidence for the intestinal contribution to 
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Figure 3-2 Summary of previously known and current effects of nobiletin in a 
mouse model of the metabolic syndrome. 
In Ldlr-/- mice, previous studies investigated nobiletin’s mechanism of action with a 
primary focus on the liver (left). Nobiletin reduces apoB100 secretion by reducing 
SREBP-1c-mediated lipogenesis and increasing fatty acid oxidation. Correspondingly, 
nobiletin attenuates plasma TG and cholesterol levels. Nobiletin prevents adiposity, 
improves insulin sensitivity and increases glucose uptake in muscle. Whole-body energy 
expenditure is enhanced by nobiletin. In this thesis, the protection by nobiletin in the 
intestine as well as other tissues was investigated in male (right in bold) and female mice 
(pink bold). Novel findings from studies in this thesis are indicated in bold. Nobiletin 
decreased fasting jejunal lipid accumulation by correcting intestinal insulin signaling and 
thereby normalizing de novo lipogenesis (DNL). Nobiletin increased chylomicron-TG 
(CM-TG) secretion into plasma in response to an oral fat load, a mechanism independent 
of GLP-2. Following an oral fat load, nobiletin increased CM-TG clearance. Nobiletin 
prevented fasting and post-glucose load hyperinsulinemia through a correction of incretin 
GIP secretion and a prevention of β-cell mass expansion. The metabolic protection by 
nobiletin was investigated in female Ldlr-/- (pink). Nobiletin prevented obesity and 
normalized plasma and hepatic TG levels. However, nobiletin did not correct plasma and 
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